Drugs

, Volume 36, Issue 5, pp 540–600

Captopril

An Update of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure
  • Rex N. Brogden
  • Peter A. Todd
  • Eugene M. Sorkin
Drug Evaluation

Summary

Synopsis

Captopril is an orally active inhibitor of angiotensin-converting enzyme (ACE) and has been widely studied in the treatment of patients with mild to moderate essential hypertension, severe hypertension not responsive to conventional diuretic/β-adrenoceptor blocker/vasodilator regimens, and patients with chronic congestive heart failure refractory to treatment with a diuretic and digitalis.

In patients with mild or moderate essential hypertension, titrated low doses of captopril used alone or in conjunction with a diuretic are similar in efficacy to usual doses of hydrochlorothiazide, chlorthalidone, or β-adrenoceptor blocking drugs, as well as to the other ACE inhibitors. In addition, captopril improved well-being to a greater extent than methyldopa or propranolol in a study designed specifically to determine the effect of treatment on the quality of life of patients with mild or moderate essential hypertension. The earlier demonstrated efficacy of captopril, used with a diuretic and often also with a β-adrenoceptor blocking drug, in the treatment of severe hypertension refractory to conventional ‘triple therapy’ has been confirmed in more recent trials which illustrate the generally marked antihypertensive effect of captopril-containing regimens in such patients. Results of initial trials in patients with scleroderma are promising, with control of hypertension and stabilisation of renal function in these patients when treated at an early stage of the disease.

Several comparative and long term trials of captopril in patients with chronic congestive heart failure refractory to treatment with a diuretic/digitalis regimen clearly demonstrate that initial haemodynamic improvement is maintained and correlates with clinical benefit. A tendency for overall clinical response to captopril to be better than the response to prazosin, hydralazine, nisoldipine or enalapril has been reported. Results of a multicentre comparison with digoxin and placebo indicate that captopril is a suitable alternative to digoxin in patients with mild to moderate heart failure who are receiving maintenance diuretic therapy.

The tolerability of captopril has now been studied in many thousands of patients involved in formalised trials and the early impression of poor tolerability can no longer be justified. The use of generally lower dosages of captopril in patients with normal or slightly impaired renal function has resulted in a generally low incidence of rash (0.5 to 4%), dysgeusia (0.1 to 3%), proteinuria (0.5%), neutropenia (0.3% during first 3 months) and symptomatic hypotension (0.1 to 3%). Cough is an infrequent but troublesome effect resulting from ACE inhibition. The risk of these adverse effects is substantially increased when captopril is used at high dosages in patients with impaired renal function.

Thus, captopril with its generally good tolerability and proven long term efficacy warrants consideration as a ‘first line’ therapy in patients with mild or moderate essential hypertension and in patients with refractory hypertension, and as a drug of choice in patients with chronic congestive heart failure when digitalis is poorly tolerated or ineffective.

Pharmacodynamic Properties

Inhibition of the renin-angiotensin-aldosterone system by pharmacological intervention produces favourable haemodynamic changes which benefit patients with hypertension or congestive heart failure. The acute effects of orally administered captopril include inhibition of angiotensin-converting enzyme (ACE) activity, decreased and increased plasma concentrations of angiotensin II and angiotensin I, respectively, increased plasma renin activity or renin concentration, and decreased aldosterone concentration or urinary aldosterone excretion. Maximal hormonal responses are usually noted after about 1 hour and return to control levels after about 6 to 8 hours, although recovery of ACE activity can take up to 12 to 14 hours. The acute changes in the renin-angiotensin-aldosterone system are generally maintained during long term captopril treatment. The blood pressure lowering effect of ACE inhibition by captopril is most pronounced in subjects with high pretreatment plasma renin activity, and response to the drug is enhanced by sodium restriction or diuretic therapy which increase dependence on plasma renin activity.

Repeated oral administration of usual therapeutic doses of captopril has reportedly decreased urinary kallikrein and increased circulating concentrations of bradykinin in some studies, but not in others. It has become increasingly evident that plasma concentrations of prostaglandin E2 and I2 (prostacyclin), or concentrations of their metabolites in urine, may be increased during treatment with captopril in patients with hypertension or congestive heart failure. That the haemodynamic responses to captopril may be partially mediated by prostaglandins is suggested by the attenuation of the antihypertensive effect of captopril by concomitant indomethacin. Adrenaline (epinephrine) plasma concentrations were not influenced by captopril treatment, while mean noradrenaline (norepinephrine) concentrations were unchanged in some studies but were decreased in individuals with high pretreatment concentrations.

The acute haemodynamic changes in hypertensive patients after a single oral dose of captopril, which are maximal within 1 hour and persist for 8 to 12 hours, consist of a decrease in systolic and diastolic blood pressure and in systemic vascular resistance, usually without clinically significant changes in heart rate or cardiac output. Maximal effects are usually produced by doses of captopril 12.5 to 25mg while increases in dose above this may increase the duration of the response.

In patients with congestive heart failure, a single dose of captopril causes a significant decrease of about 37 to 45% in right atrial pressure, pulmonary capillary wedge pressure, and pulmonary and systemic vascular resistances within 30 to 90 minutes; mean arterial and pulmonary artery pressures decrease by 24 to 30%. Cardiac output, cardiac index, stroke index and stroke work index increase by about 20 to 44%.

The beneficial haemodynamic effects of captopril are maintained during long term treatment and are accompanied by clinical improvement. Most studies have shown some degree of statistically significant correlation between high pretreatment renin levels and more marked acute haemodynamic response, although any correlation between pretreatment renin levels and long term haemodynamic or clinical response was frequently absent.

Compared with other vasodilator drugs such as hydralazine, prazosin, sodium nitroprusside or nitrates, captopril exerts a relatively weak effect in reducing pulmonary vascular resistance. However, the effect of captopril on preload and afterload is balanced and thus resembles that of prazosin, amrinone and isosorbide dinitrate, although quantitatively the effect of captopril was sometimes greater than that of prazosin and less than that of amrinone.

In healthy subjects the renal haemodynamic and functional response to ACE inhibition depends on the state of the renin-angiotensin system. Restriction of sodium intake markedly increases the renal response to captopril, resulting in increased renal blood flow, reversal of the decrease in glomerular filtration rate, decreased renal vascular resistance and a substantial natriuresis. Long term administration of captopril to patients with essential hypertension has usually resulted in little change in mean values for renal blood flow, effective renal plasma flow or glomerular filtration rate. In patients with renovascular hypertension and unilateral lesions glomerular filtration decreased (sometimes markedly) on the stenotic side, but was little changed on the non-stenotic side. Mean sodium excretion was increased in some patients with essential hypertension but not in others, while mean potassium excretion was unchanged during long term treatment. Divergent findings and considerable interindividual variation in the acute effects of captopril on renal blood flow and indices of renal function have been reported in patients with chronic congestive heart failure. Thus, both an increase and a decrease in renal blood flow have been noted, although different findings may have been related to concomitant diuretic administration in some patients. In 1 study a decrease in renal blood flow occurred when mean arterial blood pressure was reduced to below 60mm Hg. As in patients with hypertension, renal vascular resistance was consistently decreased in patients with congestive heart failure. Serum potassium concentrations have increased in some patients, but remained stable during long term captopril therapy in others receiving a thiazide diuretic plus triamterene.

Pharmacokinetic Properties

Approximately 70% of an oral dose of captopril is absorbed by healthy fasting subjects and absolute bioavailability is about 60% compared with the intravenous route. Mean maximum blood concentrations after single oral doses of captopril are dose-related over the range from 10 to 100mg and are about 1.6 to 1.9 mg/L (total drug) after oral administration of 100mg. The area under the plasma concentration-time curve for free captopril was similar in healthy subjects and in patients with hypertension or congestive heart failure after repeated doses, while that for total captopril increased by around 20%. Bioavailability is decreased by 25 to 50% when captopril is coadministered with food, and is similarly decreased when the drug is given with antacids. However, food does not alter either the magnitude or timing of the antihypertensive effect of captopril. In healthy subjects the mean volume of distribution at steady state was about 0.7 L/kg; a value of 2.05 L/kg during the terminal phase indicated extensive partitioning into tissues.

The metabolism of captopril is complex and yet to be fully elucidated. In man, captopril is partially metabolised (about 50%), mainly by disulphide formation with endogenous thiol compounds including glutathione, cysteine and proteins. One of these metabolites, S-methyl captopril, is present in the circulation at concentrations of 60 to 114 µg/L after a single oral dose of captopril 100mg in healthy subjects. Most of the drug is excreted unchanged in the urine by tubular secretion, 94% of this being recovered within 6 hours. Elimination half-life has been difficult to calculate, with reported values of 0.35 to 0.66 hours and 1.7 to 1.9 hours, depending on the method used.

The pharmacokinetic properties of captopril in patients with hypertension and in the elderly are similar to those in healthy subjects. While mean pharmacokinetic values in patients with chronic congestive heart failure are not generally different, between-subject variability is more marked than in healthy subjects. Individual elimination rate constants are linearly related to endogenous creatinine clearance in patients with renal impairment, resulting in an increased half-life and reduced clearance of captopril in patients with renal impairment. Since ACE inhibition and antihypertensive response may be prolonged in patients with renal functional impairment, dosage modification according to the degree of impairment is necessary. Captopril is removed by haemodialysis more efficiently than its metabolites. Since free or total plasma captopril concentrations have not correlated well with haemodynamic or neurohormonal responses in individual patients, monitoring of plasma concentrations is of little value in establishing optimum dosage.

Therapeutic Trials

Captopril has been widely studied in patients with mild to moderate essential hypertension in whom, at dosages often less than 200mg daily, it has been compared with other ACE inhibitors, β-adrenoceptor blocking drugs and various diuretics. In many studies in mild to moderate essential hypertension captopril was used in conjunction with a diuretic (most often hydrochlorothiazide), which clearly resulted in enhanced antihypertensive efficacy. Most studies comparing captopril with 1 or more other antihypertensive drugs have involved relatively small numbers of patients, thus decreasing the likelihood of differences between drugs being statistically significant; however, in many studies dosages were titrated to optimum levels and results reported in the few larger studies were consistent with those in the smaller trials.

Captopril 75 to 300mg daily in 3 divided doses was closely comparable with enalapril 10 to 40mg in 2 doses daily when used in conjunction with methyldopa to reduce blood pressure to target levels. In 1 study captopril 50 to 100mg once daily was similar in efficacy to enalapril 10 to 20mg once daily, while in another study captopril 100mg daily and ramipril 10mg daily were similarly effective when both drugs were administered twice daily. In some cases enalapril was reported to be more effective than captopril at some time points during particular studies, but differences were not statistically significant at the end of the trials. Similarly, there were no significant differences in the therapeutic efficacy of captopril and various β-adrenoceptor blocking drugs or labetalol in patients with mild or moderate hypertension, either when doses were titrated to individual requirements or when fixed combinations were used. Studies comparing titrated doses or predetermined fixed doses of captopril and hydrochlorothiazide, chlorthalidone or triamterene plus hydrochlorothiazide, have noted no statistically significant differences in efficacy between treatments in patients with mild to moderately severe uncomplicated hypertension. Captopril 50 to 300mg daily was also comparable with nifedipine 40 to 80mg or minoxidil 5 to 40mg (mean 7.5mg) when added to existing ineffective treatment regimens.

While captopril alone is effective in lowering mildly or moderately elevated blood pressure in many patients, studies comparing the efficacy of captopril alone with that of captopril plus a diuretic, or occasionally other antihypertensive drugs, have clearly demonstrated an advantage for combined administration. A study in a large group of patients reported a similar decrease in blood pressure with either captopril 37.5, 75 or 150mg daily in patients allocated at random, and further improved control of blood pressure following the addition of hydrochlorothiazide. Several other studies similarly report improved efficacy with captopril used in conjunction with a diuretic or a calcium antagonist, relative to either drug alone.

The earlier reported efficacy of captopril used in conjunction with a diuretic and (usually) a β-adrenoceptor blocking drug in patients with hypertension not adequately controlled with conventional ‘triple therapy’ has been confirmed by more recent studies. These studies have demonstrated the generally marked antihypertensive effects of captopril-containing regimens in refractory hypertension. The addition of captopril to an existing diuretic/β-adrenoceptor blocker regimen resulted in a decrease in supine diastolic blood pressure of 12 to 29% over a period of several months. The decrease in blood pressure was more pronounced in patients with renovascular or renal parenchymatous hypertension than in those with essential hypertension. In small numbers of patients whose blood pressure was not controlled by maximum tolerated doses of either captopril or minoxidil added to a diuretic/β-adrenoceptor blocker regimen, treatment with captopril plus minoxidil in addition to the diuretic and β-blocker resulted in a satisfactory mean reduction in blood pressure.

Long term trials of captopril alone or in conjunction with a diuretic clearly indicate that the antihypertensive effect of titrated doses of captopril is maintained and that tolerance to this effect does not develop.

Studies undertaken to determine the effect of captopril, methyldopa and β-adrenoceptor blocking drugs on the quality of life have, with 1 notable exception, been poorly designed. However, in the best designed trial, captopril resulted in improved quality of life relative to methyldopa and relative to propranolol for some assessment criteria.

In many studies, twice daily administration of captopril alone or in conjunction with a diuretic has been effective in decreasing blood pressure to target levels in patients with mild or moderate essential hypertension. It was considered that once daily administration may provide satisfactory control in such patients, and there is some evidence that this is so. However, further trials utilising 24-hour monitoring of blood pressure and comparing once and twice daily regimens are needed.

Captopril, usually at dosages of less than 150mg daily, has proved an effective and generally well tolerated drug in elderly or diabetic patients with uncomplicated hypertension. Initial studies in children with ‘renal’ hypertension have reported captopril 0.3 to 6 mg/kg/day to effectively control blood pressure, including that not responsive to other drugs. Recent studies have described the satisfactory antihypertensive effect of captopril in conjunction with a diuretic and (usually) other drugs in the treatment of refractory hypertension associated with renal transplantation. Renal function improved in many patients in whom treatment with captopril was started less than 1 year after transplantation. Renal function appeared more likely to deteriorate in sodium-depleted patients and in those with pre-existing renal impairment and a greater than 75% narrowing of the main renal artery. Recent studies of captopril in patients with scleroderma are promising, particularly in those treated at an early stage. In such patients captopril 32 to 150 mg/day plus frusemide (furosemide) controlled hypertension and stabilised renal function where pretreatment serum creatinine was less than 442 µmol/L (5 mg/dl).

At the time that the use of captopril in chronic congestive heart failure was previously reviewed in the Journal there were few comparative studies. Subsequently, comparative data have been reported, and it has also been established that the acute haemodynamic effects of captopril are maintained during long term administration and are accompanied by clinical improvement in patients with chronic congestive heart failure refractory to diuretic and digitalis therapy. Titrated doses of captopril (37.5 to 150 mg/day) were more effective than placebo as evidenced by a reduction in NYHA functional rating or class and in symptoms, and an improvement in exercise capacity in patients with congestive heart failure not responsive to diuretics and digitalis. Similarly, in patients with mild to moderate heart failure captopril improved exercise time and NYHA functional rating relative to placebo whereas digoxin did not. Captopril 300mg daily was superior to prazosin 15mg daily when the drugs were directly compared and diuretic dosage was kept constant. Captopril has also been at least as effective as nisoldipine, hydralazine and enalapril in small groups of patients with chronic refractory heart failure. In mild heart failure, however, substitution of captopril 75mg daily for established diuretic therapy did not result in clinical improvement. Clinical responses to captopril 150mg and enalapril 40mg daily were not significantly different in patients whose pretreatment ejection fraction was below 30%, although side effects were more often a problem with enalapril. There do not appear to be any biochemical or haemodynamic characteristics that reliably predict a favourable clinical response to captopril in patients with chronic congestive heart failure. There is some evidence that the improved clinical state afforded by captopril treatment results in prolongation of survival. Over a period of 12 months treatment with captopril attenuated the progressive enlargement of the ventricular chamber in patients with symptomless left ventricular dysfunction following myocardial infarction.

Side Effects

Although early clinical experience with captopril in patients with severe complicated hypertension, frequently accompanied by renal impairment, and often involving higher doses than are now usually employed, suggested that captopril was not well tolerated, more recent clinical experience with many thousands of patients with mild to moderate uncomplicated hypertension or chronic congestive heart failure indicates that captopril is generally well tolerated in patients with normal or only mildly impaired renal function. Captopril at dosages lower than 150mg daily has caused rash, dysgeusia, hypotensive symptoms and proteinuria in 0.5 to 4.3, 0.1 to 2.7, 0.2 to 4.4 and 0.5% of patients, respectively. Non-productive cough has been reported in 0.2 to 4.4% of patients and appears to be a class effect of ACE inhibitors. The risk of significant side effects was greatest during the first few months of treatment, with daily dosages exceeding 150mg, and in patients with pre-existing renal disease. In post-marketing surveillance studies neutropenia has occurred in up to 0.3% of patients during the first 3 months of treatment with captopril but was not reported over the next 45 months.

Dosage and Administration

When treating hypertension or congestive heart failure it is important to titrate the dosage of captopril to suit individual patient requirements. The usual initial dosage of captopril in hypertension and congestive heart failure is 50mg daily as a single or in two divided doses. However, a much lower dosage of 6.25 or 12.5mg may be required in sodium- or volume-depleted patients. In patients with hypertension, dosage may be increased to 100 or 150mg daily if necessary, but a diuretic should be added before captopril dosage is increased further. The dosage of captopril should not exceed 450mg daily. In patients with congestive heart failure captopril should be administered with a diuretic, and once a dose of 150mg daily is reached further dosage increases should be delayed, where possible, for at least 2 weeks to determine if a satisfactory response occurs. Again, the maximum dosage of captopril should not exceed 450mg daily. In children the initial dose of captopril is 0.3 mg/kg, although 0.15 mg/kg may be appropriate in those likely to develop hypotension. The dosage in children should not exceed 6 mg/kg/day.

Patients with renal impairment should have their dosage of captopril adjusted by either decreasing the total daily dosage or by increasing the interval between each dose. When a diuretic is required in patients with severe renal impairment a loop diuretic (e.g. frusemide), rather than a thiazide, is preferred.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abe K. The interaction of renin-angiotensin-aldosterone system and renal depressor system. Japanese Journal of Medicine 21: 141–146, 1982PubMedGoogle Scholar
  2. Abe K, Itoh T, Satoh M, Haruyama T, Imai Y, et al. Indomethacin (ind) inhibits an enhanced renin release following captopril, SQ 14225, administration. Life Sciences 26: 561–565, 1980PubMedGoogle Scholar
  3. Åberg H, Frithz G, Mörlin C. Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 368–371, 1981Google Scholar
  4. ACE Report 48. Cough and angiotensin converting enzyme inhibition. Merck and Co. Ltd, March, 1988Google Scholar
  5. Ajayi AA, Campbell BC, Rubin PC, Reid JL. Effect of naloxone on the actions of captopril. Clinical Pharmacology and Therapeutics 38: 560–565, 1985PubMedGoogle Scholar
  6. Albertazzi A, Del Rosso G, Cappelli P, Spisni C, Evangelista M. Clinical experience with captopril in the treatment of severe and resistant hypertension. Drugs under Experimental Clinical Research 8: 529–540, 1982Google Scholar
  7. Aldigier J-C, Plouin P-F, Guyere TT, Thibonnier M, Corvol P, et al. Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. American Journal of Cardiology 49: 1447–1452, 1982PubMedGoogle Scholar
  8. Al Mahdy H, Boswell GV. Captopril-induced oesophagitis. European Journal of Clinical Pharmacology 34: 95, 1988PubMedGoogle Scholar
  9. Anderson GH, Springer J, Tivnan E, Kearney M, Streeter DHP. Hypotensive mechanism of captopril. Clinical Research 28: 328A, 1980Google Scholar
  10. Ando K, Fujita T, Ito Y, Noda H, Yamashita K. The role of renal hemodynamics in the antihypertensive effect of captopril. American Heart Journal 111: 347–352, 1986PubMedGoogle Scholar
  11. Andrén L, Karlberg B, Öhman P, Svensson A, Asplund J, et al. Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. British Journal of Clinical Pharmacology 14: 107S–111S, 1982PubMedGoogle Scholar
  12. Andrén L, Karlberg BE, Svensson A, Öhman P, Nilsson OR, et al. Long term effects of captopril and atenolol in essential hypertension. Acta Medica Scandinavica 217: 155–160, 1985PubMedGoogle Scholar
  13. Aranda P, Aranda JM, Carmona JR, Nuñez D. Captopril as first step therapy in elderly hypertensive diabetic patients. Abstract. Postgraduate Medical Journal 64(Suppl. 3): 87, 1988Google Scholar
  14. Aranda-Lara P, Gras-Balaguer X, Cabello M, Martín-Reyes G, Valera A, et al. Tratamiento de la hipertensión arterial esencial del anciano con captopril e hidrochlorotiazida a bajas dosis. Estudio a largo plazo. Revista Clinica Española 181: 185–189, 1987PubMedGoogle Scholar
  15. Assyag P, Koenig A, Fas H, Brechenmacher C. Agranulocytose au captopril. Annales de Cardiologie et d’Angéiologie 36: 81–83, 1987PubMedGoogle Scholar
  16. Atkinson AB, Brown JJ, Fraser R, Leckie B, Lever AF, et al. Captopril in hypertension with renal artery stenosis and in intractable hypertension: acute and chronic changes in circulating concentrations of renin, angiotensin I and II and aldosterone, and in body composition. Clinical Science 57: 139S–143S, 1979PubMedGoogle Scholar
  17. Atkinson AB, Cumming AMM, Brown JJ, Fraser R, Leckie B, et al. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure. British Journal of Clinical Pharmacology 13: 855–858. 1982PubMedGoogle Scholar
  18. Atlas SA, Case DB, Scaley JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1: 274–280, 1979PubMedGoogle Scholar
  19. Atlas SA, Case DB, Yu ZY, Laragh JH. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors: possible differences between enalapril and captopril. American Journal of Medicine 77: 13–17, 1984PubMedGoogle Scholar
  20. Augenstein WL, Kulig KW, Rumack BH. Captopril overdose resulting in hypotension. Journal of the American Medical Association 259: 3302–3305, 1988PubMedGoogle Scholar
  21. Awan NA, Amsterdam EA, Hermanovich J, Bommer WJ, Needham KE, et al. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure. American Heart Journal 103: 474–479, 1982PubMedGoogle Scholar
  22. Awan NA, Mason DT. Vasodilator therapy of severe congestive heart failure: the special importance of angiotensin-converting enzyme inhibition with captopril. American Heart Journal 104: 1127–1136, 1982PubMedGoogle Scholar
  23. Baker SL. A study of the use of captopril in elderly hypertensive patients. Age and Ageing 17: 17–20, 1988PubMedGoogle Scholar
  24. Bass TA, Faxon DP, Halperin JL, Creager MA, Melidosian CD, et al. Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure. Clinical Research 29: 176A, 1981Google Scholar
  25. Bathala MS, Weinstein SH, Meeker Jr FS, Singhri SM, Migdalof BH. Quantitative determination of captopril in blood and captopril and its disulfide metabolites in plasma by gas chromatography. Journal of Pharmaceutical Sciences 73: 340–344, 1984PubMedGoogle Scholar
  26. Bayliss J, Canepa-Anson R, Norell MS, Poole-Wilson P, Sutton G. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. British Heart Journal 55: 265–273, 1986PubMedGoogle Scholar
  27. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. British Medical Journal 290: 1861–1865, 1985PubMedGoogle Scholar
  28. Beckett VL, Donadio JV, Brennan LA, Conn DL, Osmundson PJ, et al. Use of captopril as early therapy for renal scleroderma: a prospective study. May Clinic Proceedings 60: 763–771, 1985Google Scholar
  29. Bernini G, Taddei S, Graziadei L, Pedrinelli R, Salvetti A. Naloxone does not modify the antihypertensive effect of captopril in essential hypertensive patients. Journal of Hypertension 3(Suppl. 2): S117–119, 1985PubMedGoogle Scholar
  30. Bertoli L, Fusco M, Lo Cicero S, Micallef E, Busnardo I. Influence of ACE inhibition on pulmonary haemodynamics and function in patients in whom beta-blockers are contraindicated. Postgraduate Medical Journal 62(Suppl. 1): 47–51, 1986PubMedGoogle Scholar
  31. Bhat OM, Mitra DK, Patel K, Oke VG, Rajkotmala VA, et al. Double comparative trial of captopril versus methyldopa in mild and moderate hypertension. Current Therapeutic Research 40: 92–98, 1986Google Scholar
  32. Bifano E, Post EM, Springer J, Williams ML, Streeten DHP. Treatment of neonatal hypertension with captopril. Journal of Pediatrics 100: 143–146, 1982PubMedGoogle Scholar
  33. Bouissou F, Meguira B, Rostin M, Fontaine C, Charlet JP, et al. Long term therapy by captopril in children with renal hypertension. Clinical and Experimental Hypertension — Theory and Practice 8: 841–845, 1986Google Scholar
  34. Bounhowe JP, Kayanakis JG, Fauvel JM, Puel J. Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction. British Journal of Clinical Pharmacology 14(Suppl. 2): 187S–191S, 1982Google Scholar
  35. Boutroy M-J, Vert P, Hurault de Ligny B, Miton A. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet 2: 935–936, 1984PubMedGoogle Scholar
  36. Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1: 39–46, 1979PubMedGoogle Scholar
  37. Britton KE, Granowska M, Nimmon CC, Home T. Cerebral blood flow in hypertensive patients with cerebrovascular disease: technique for measurement and effect of captopril. Nuclear Medicine Communications 6: 251–261, 1985PubMedGoogle Scholar
  38. Brouwer RML, Bolli P, Erné P, Conen D, Kiowski W, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. Journal of Cardiovascular Pharmacology 7: S88–S91, 1985PubMedGoogle Scholar
  39. Brunner HR, Gavras H, Waeber B, Textor SC, Turini GA, et al. Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension 2: 558–566, 1980PubMedGoogle Scholar
  40. Bünning P. Inhibition of angiotensin converting enzyme by 2-[N-[(s)-l-carboxy-3-phenylpropyl]-L-alanyl]-(lS, 3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) diacid: comparison with captopril and enalaprilat. Arzneimittel-Forschung 34: 1406–1410, 1984PubMedGoogle Scholar
  41. Burke CM, Harte M, Duncan J, Connolly HM, Horgan JH, et al. Captopril and domiciliary oxygen in chronic airflow obstruction. British Medical Journal 290: 1251, 1985PubMedGoogle Scholar
  42. Callis L, Vila A, Catala J, Gras X. Long term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure. Clinical and Experimental Hypertension — Theory and Practice 8: 847–851, 1986Google Scholar
  43. Campbell DJ. Circulating and tissue angiotensin systems. Journal of Clinical Investigation 79: 1–6, 1987PubMedGoogle Scholar
  44. Cantelli I, Vitolo A, Lombardi G, Bomba E, Bracchetti D. Combined haemodynamic effects of digoxin and captopril in patients with congestive heart failure. Current Therapeutic Research 36: 323–331, 1984Google Scholar
  45. Captopril Collaborative Study Group. Does captopril cause renal damage in hypertensive patients? Lancet 1: 988–990, 1982Google Scholar
  46. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Journal of the American College of Cardiology 2: 755–763, 1983Google Scholar
  47. Captopril Multicenter Research Group. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long term response. American Heart Journal 110: 439–447, 1985Google Scholar
  48. Captopril Research Group of Japan. Clinical effects of low-dose captopril plus a thiazide diuretic on mild to moderate essential hypertension. A multicenter double-blind comparison with propranolol. Journal of Cardiovascular Pharmacology 7(Suppl. 1): S77–S81, 1985Google Scholar
  49. Case DB, Atlas SA, Laragh JH. Reactive hyperreninemia to angiotensin blockade identified renovascular hypertension. Clinical Science 57 (Suppl.): 313S–316S, 1979PubMedGoogle Scholar
  50. Case DB, Atlas SA, Marion RM, Laragh JH. Long term efficacy of captopril in renovascular and essential hypertension. American Journal of Cardiology 49: 1440–1446, 1982aPubMedGoogle Scholar
  51. Case DB, Atlas SA, Marion RM, Nicholson JP, Parnassa E, et al. Clinical experience with captopril in moderate to severe hypertension. Cardiovascular Reviews and Reports 3: 435–453, 1982bGoogle Scholar
  52. Catalano M, Libretti A. Captopril for the treatment of patients with hypertension and peripheral vascular disease. Angiology 36: 293–296, 1985PubMedGoogle Scholar
  53. Chakraborty TK, Ruddell WSJ. Guillain-Barré neuropathy during treatment with captopril. Postgraduate Medical Journal 63: 221–222, 1987PubMedGoogle Scholar
  54. Chalmers D, Dombey SL, Lawson DH. Postmarketing surveilance of captopril for hypertension: a preliminary report. British Journal of Clinical Practice 24: 343–349, 1987Google Scholar
  55. Chan MK, Sweny P, Nahas AM, Farrington K, Fernando ON, et al. Captopril in hypertension after renal transplantation. Postgraduate Medical Journal 60: 132–134, 1984PubMedGoogle Scholar
  56. Chatterjee K, Rouleau J-L, Parmley WW. Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure. British Heart Journal 47: 233–238, 1982PubMedGoogle Scholar
  57. Chen D-S, Brunner HR, Waeber B. In-vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors. Current Therapeutic Research 35: 253–262, 1984Google Scholar
  58. Chrysant SG, Bal IS, Johnson B, McPherson M. A comparative study of captopril and enalapril in patients with severe hypertension. Journal of Clinical Pharmacology 25: 149–151, 1985PubMedGoogle Scholar
  59. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson JIS, et al. Captopril in heart failure: a double blind controlled trial. British Heart Journal 52: 530–535, 1984PubMedGoogle Scholar
  60. Cleland JGF, Dargie HJ, Pettigrew A, Gillen G, Robertson JIS. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. American Heart Journal 112: 130–135, 1986PubMedGoogle Scholar
  61. Clough DP, Collis MG, Conway J, Hatton R, Keddie JR. Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system. American Journal of Cardiology 49: 1410–1414, 1982PubMedGoogle Scholar
  62. Cody RJ. The effect of captopril on postural hemodynamics and autonomic responses in chronic heart failure. American Heart Journal 104: 1190–1196, 1982PubMedGoogle Scholar
  63. Cody RJ. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure: a review. Drugs 28: 144–169, 1984PubMedGoogle Scholar
  64. Cody RJ, Covit A, Schaer G, Williams G. Captopril pharmacokinetics in chronic heart failure: correlation with acute hemodynamic and hormonal response. Abstract. Clinical Pharmacology and Therapeutics 31: 211, 1982aGoogle Scholar
  65. Cody RJ, Covit A, Schaer G, Williams G. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe congestive heart failure. American Heart Journal 104: 1180–1183, 1982bPubMedGoogle Scholar
  66. Cody RJ, Franklin KW, Kluger J, Laragh JH. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. American Journal of Medicine 72: 791–797, 1982dPubMedGoogle Scholar
  67. Cody RJ, Franklin KW, Laragh JH. Combined vasodilator therapy for chronic congestive heart failure. American Heart Journal 105: 575–580, 1983PubMedGoogle Scholar
  68. Cody RJ, Schaer GL, Covit Ab, Pondolfino K, Williams G. Captopril kinetics in chronic congestive heart failure. Clinical Pharmacology and Therapeutics 32: 721–726, 1982cPubMedGoogle Scholar
  69. Cohen AI, Devlin RG, Ivashkir E, Furke PT, McCormick T. Determination of captopril in human blood and urine by GLC-selected ion monitoring mass spectrometry after oral coadministration with its isotopomer. Journal of Pharmaceutical Sciences 71: 1251–1256, 1982PubMedGoogle Scholar
  70. Cohen AI, Ivashkir E, McCormick T, McKinstry DN. Identification and determination of the S-methyl metabolite of captopril in human plasma by selected-ion monitoring gas chromatography-mass spectrometry. Journal of Pharmaceutical Sciences 73: 1493–1495, 1984PubMedGoogle Scholar
  71. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New England Journal of Medicine 316: 1430–1435, 1987Google Scholar
  72. Cooper RA. Captopril-associated neutropenia. Archives of Internal Medicine 143: 659–660, 1983PubMedGoogle Scholar
  73. Corcoran JS, Perkins JE, Hoffbrand BI, Yudkin JS. Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine and captopril combined with bendrofluazide. Diabetic Medicine 4: 164–168, 1987PubMedGoogle Scholar
  74. Corea L, Bentivoglio M, Verdecchia P. Captopril compared with nifedipine in the treatment of heart failure: a randomized study. Drugs Under Experimental and Clinical Research 9: 901–910, 1983aGoogle Scholar
  75. Corea L, Bentivoglio M, Verdecchia P. Low dose captopril therapy in mild and moderate hypertension. Hypertension 5(Suppl. III): 157–159, 1983bGoogle Scholar
  76. Corea L, Bentivoglio M, Verdecchia P, Providenza M. Converting enzyme inhibition vs diuretic therapy as first therapeutic approach to the elderly hypertensive patient. Current Therapeutic Research 36: 347–351, 1984Google Scholar
  77. Costa FV, Borghi C, Ambrosioni E. Captopril and oxprenolol in a fixed combination with thiazide diuretics: comparison of their antihypertensive efficacy and metabolic effects. Clinical Therapeutics 6: 708–718, 1984aPubMedGoogle Scholar
  78. Costa FV, Borghi C, Ambrosioni E, Magnani B. Low doses of captopril in association with once or twice daily hydrochlorothiazide in essential hypertension: long term efficacy and safety. Current Therapeutic Research 36: 181–187, 1984bGoogle Scholar
  79. Costa FV, Borghi C, Boschi S, Ambrosioni E. Differing dosages of caplopril and hydrochlorothiazide in the treatment of hypertension: long term effects on metabolic values and intracellular electrolytes. Journal of Cardiovascular Pharmacology 7: S70–S76, 1985PubMedGoogle Scholar
  80. Coulter DM. Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance. British Medical Journal 296: 1086–1088, 1988PubMedGoogle Scholar
  81. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. British Medical Journal 294: 1521–1523, 1987PubMedGoogle Scholar
  82. Cowley AJ, Rowley JM, Stavier K, Hampton JR. Effects of captopril on abnormalities on the peripheral circulation and respiratory function in patients with severe heart failure. Lancet 2: 1120–1124, 1984PubMedGoogle Scholar
  83. Creager MA, Faxon DP, Weiner DA, Ryan TJ. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril. British Heart Journal 53: 431–435, 1985PubMedGoogle Scholar
  84. Creager MA, Halperin JL, Bernard DB, Faxon DF, Melidossian CD, et al. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 64: 483–489, 1981PubMedGoogle Scholar
  85. Creasey WA, Funke PT, McKinstry DN, Sugerman AA. Pharmacokinetics of captopril in elderly healthy male volunteers. Journal of Clinical Pharmacology 26: 264–268, 1986PubMedGoogle Scholar
  86. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual symptoms in hypertensive patients. Archives of Internal Medicine 148: 788–794, 1988PubMedGoogle Scholar
  87. Croog SH, Levine S, Testa MA, Brouen B, Bulpitt CJ. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 26: 1657–1664, 1986Google Scholar
  88. Crossley IR, Bihari D, Gimson AES, Westabay D, Richardson PJ, et al. Effects of converting enzyme inhibitor on hepatic blood flow in man. American Journal of Medicine 76: 62–65, 1984PubMedGoogle Scholar
  89. Cunningham RJ, Brouhard BH. Captopril and kallikrein. Lancet 1: 832, 1980PubMedGoogle Scholar
  90. D’Angelo A, Giannini S, Benetollo P, Castrignano R, Giuseppina Lodetti M, et al. Efficacy of captopril in hypertensive diabetic patients. American Journal of Medicine 84(Suppl. 3A): 155–158, 1988PubMedGoogle Scholar
  91. D’Angelo A, Sartori L, Gambaro G, Giannini S, Malvasi L, et al. Captopril in the treatment of hypertension in type I and type II diabetic patients. Postgraduate Medical Journal 62(Suppl. 1): 69–72, 1986PubMedGoogle Scholar
  92. Davidson D, Stalcup SA, Mellins RB. Captopril administration to the pregnant guinea pig inhibits fetal angiotensin converting enzyme activity. Pediatric Research 15: 658, 1981Google Scholar
  93. de Bruyn BJH, Verhoeven RP, Boomsa F, Man in’t Veld AJ, Wenting GJ, et al. Long term effects of converting enzyme inhibition on systemic and renal haemodynamics, body fluid volumes and plasma noradrenaline in essential hypertension. Proceedings of the 6th Scientific Meeting of the International Society of Hypertension, Goteborg, Sweden, June, 1979Google Scholar
  94. De Cesaris R, Ranieri G, Salzano EV, Liberatore SM. Once daily therapy with angiotensin converting enzyme inhibitors in mild hypertension: a comparison of captopril and enalapril. Journal of Hypertension 5(Suppl. 5): 595–597, 1987Google Scholar
  95. Dessi-Fulgheri P, Bandiera F, Glorioso N, Rubattu SD, Palmermo M, et al. Labetolol and captopril combined with chlorthalidone in the treatment of mild to moderate essential hypertension. Current Therapeutic Research 37: 873–880, 1985Google Scholar
  96. DeVenuto G, Andreotti C, Mattarei M, Pegoretti G. Prolonged treatment of essential hypertension and renal function: comparison of captopril and betablockers considering microproteinuria values. Current Therapeutic Research 38: 710–718, 1985Google Scholar
  97. DeYoung JP, Ruedy N, Wright JM. The antihypertensive efficacy of captopril given once, twice, and three times daily. Current Therapeutic Research 41: 464–470, 1987Google Scholar
  98. Devlin RG, Fleiss PM. Captopril in human blood and breast milk. Journal of Clinical Pharmacology 21: 110–113, 1981PubMedGoogle Scholar
  99. DiBianco R. Angiotensin converting enzyme inhibition. Postgraduate Medicine 78: 229–248, 1985PubMedGoogle Scholar
  100. DiBianco R. Survival in patients with heart failure: focus on captopril. Clinical Therapeutics 10: 204–215, 1988PubMedGoogle Scholar
  101. Dombey S. Optimal dose of captopril in hypertension. Correspondence. Lancet 1: 529, 1983PubMedGoogle Scholar
  102. Dominguez JR, de la Calle H, Hurtado A, Robles RG, Sancho-Rof J. Effect of converting enzyme inhibitors in hypertensive patients with non-insulin dependent diabetes mellitus. Postgraduate Medical Journal 62(Suppl. 1): 66–68, 1986PubMedGoogle Scholar
  103. Donker JM, Prins EJL, Hoorntje SJ. The responsiveness to exogenous angiotensin I (AI), angiotensin II (AII) and bradykinin (BK) after incremental doses of captopril (SQ 14,225). Kidney International 16: 904, 1979Google Scholar
  104. Drayer JIM, Weber MA, Lipson JL, Megaffm BB. Differential effects of diuresis and beta-adrenoceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension. Journal of Clinical Pharmacology 22: 179–186, 1982PubMedGoogle Scholar
  105. Drummer OH, Jarrott B. The disposition and metabolism of captopril. Medicinal Research Reviews 6: 75–97, 1986PubMedGoogle Scholar
  106. Drummer OH, Jarrott B, Louis WJ. Combined gas chromatographic-mass spectrometric procedure for the measurement of captopril and sulfur-conjugated metabolites of captopril in plasma and wine. Journal of Chromatography 305: 83–93, 1984PubMedGoogle Scholar
  107. Drummer OH, Kourtis S, Jarrott B. Inhibition of angiotensin converting enzyme by metabolites of captopril. Abstract no. 24. Clinical and Experimental Pharmacology and Physiology (Suppl. 9): 12–13, 1985Google Scholar
  108. Drummer OH, Workman BS, Miach PJ, Jarrott B, Louis WJ. The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. European Journal of Clinical Pharmacology 32: 267–271, 1987PubMedGoogle Scholar
  109. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clinical Pharmacokinetics 14: 241–259, 1988PubMedGoogle Scholar
  110. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney International 25: 942–947, 1984PubMedGoogle Scholar
  111. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clinical Pharmacology and Therapeutics 31: 452–458, 1982PubMedGoogle Scholar
  112. Duchin KL, Willard DA. The effect of captopril on renal hemodynamics in hypertensive patients. Journal of Clinical Pharmacology 24: 351–359, 1984PubMedGoogle Scholar
  113. Durand D, Ader J-L, Emal V, Bories P, Girolami J-P, et al. Traitement à long terme par le captopril de l’hypertension artérielle associée à une insuffisance rénale. Archives des Maladies du Coeur et des Vaisseaux 75: 151–156, 1982PubMedGoogle Scholar
  114. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77(Suppl. I): 1–4, 1988Google Scholar
  115. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373–1379, 1980PubMedGoogle Scholar
  116. Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine 100: 777–782, 1984PubMedGoogle Scholar
  117. Edwards IR, Coulter DM, Beasley DMG, Macintosh D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand. British Journal of Clinical Pharmacology 23: 529–536, 1987PubMedGoogle Scholar
  118. Edwards CRW, Padfield PL. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet 1: 30–34, 1985PubMedGoogle Scholar
  119. El Matri A, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. British Medical Journal 283: 277–278, 1981Google Scholar
  120. El Mehairy MM, Shaker A, Ramadan M, Hamza S. Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor. British Journal of Clinical Pharmacology 11: 469–475, 1981PubMedGoogle Scholar
  121. Elving LD, de Nobel E, Thien Th. Comparison of captopril and atenolol in the treatment of hypertension in patients with diabetes mellitus. Abstract. Postgraduate Medical Journal 64(Suppl. 3): 75, 1988Google Scholar
  122. Eriksson LS, Kågedal B, Wahrer J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. American Journal of Medicine 76: 66–70, 1984PubMedGoogle Scholar
  123. Escobar-Jiminez F, Soto F, Lobon JA, Aguilar M, Campos-Pastor MM, et al. Effect of captopril at two different dosage regimens in hypertensive non-insulin dependent patients. Postgraduate Medical Journal 64(Suppl. 3): 65–68, 1988PubMedGoogle Scholar
  124. Estrada ER, Morin MI, Amenos AM, Alsina J, Gosina AB. Captopril in essential hypertension. British Journal of Clinical Pharmacology 14: 103S–105S, 1982Google Scholar
  125. Eto M, Watanabe K, Otake Y, Morikawa A, Takebe T, et al. Effects of captopril on blood pressure, metabolic control, plasma lipids, and proteinuria in elderly hypertensive diabetics. Current Therapeutic Research 43: 427–434, 1988Google Scholar
  126. Fagard R, Bulpitt C, Lijner P, Amery A. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients. Circulation 65: 33–39, 1982PubMedGoogle Scholar
  127. Favre L, Frazer MG, Hollifield JW. An orally active angiotensin I-converting enzyme inhibitor for therapy of hypertension. Clinical Research 26: 23A, 1978aGoogle Scholar
  128. Favre L, Hollifield JW, McKinstry DN. Angiotensin-converting enzyme inhibition: a new medical therapy for hypertension? Journal of the Tennessee Medical Association 71: 201–202, 1978bPubMedGoogle Scholar
  129. Faxon DP, Creager MA, Halperin JL. Regional circulatory response to converting-enzyme inhibition in congestive heart failure. British Journal of Clinical Pharmacology 14(Suppl. 2): 179S–186S, 1982PubMedGoogle Scholar
  130. Faxon DP, Creager MA, Halperin JL, Bernard DB, Ryan TJ. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. American Journal of Medicine 76: 104–110, 1984PubMedGoogle Scholar
  131. Ferguson RK, Brunner HR, Turini GA, Gavras H. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1: 775–778, 1977PubMedGoogle Scholar
  132. Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Koplin JR. Comparison of the effects of captopril, diuretic and their combination in low- and normal-renin essential hypertension. Life Sciences 30: 59–65, 1982PubMedGoogle Scholar
  133. Fernandez-Cruz A, Luque Otero M, Fernandez-Pinilla C, Martell Claros N. Captopril in the treatment of mild essential hypertension. British Journal of Clinical Pharmacology 14: 117S–120S, 1982PubMedGoogle Scholar
  134. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. British Medical Journal 294: 1119–1120, 1987PubMedGoogle Scholar
  135. Fernere M, Lachkar H, Richard J-L, Bringer J, Orsetti A, et al. Captopril and insulin sensitivity. Annals of Internal Medicine 102: 134–135, 1985Google Scholar
  136. Figulla HR, Luig H, Nieschlag F, Kreuzer H. Clinical and haemodynamic effects of nisoldipine and captopril in heart failure: a double blind comparative study of the short and long term effects (translation). Zeitschrift für Kardiologie 76: 167–174, 1987PubMedGoogle Scholar
  137. Fiocchi R, Lijnen P, Fagard R, Staessen J, Amery A, et al. Captopril during pregnancy. Lancet 2: 1153, 1984PubMedGoogle Scholar
  138. Fitzgerald DJ, O’Callaghan WG, O’Brien ET, O’Malley K, Horgan J. Comparison of captopril and hydralazine in refractory heart failure: an acute haemodynamic study. Irish Journal of Medical Science 51: 30, 1982Google Scholar
  139. Fogari R, Zoppi A, Corradi L, Poletti L, Tettamanti F, et al. Hypotensive effect of once daily administration of captopril. Current Therapeutic Research 40: 500–508, 1986Google Scholar
  140. Folli G, Pozzoli G, Di Tullio M, Tarolo GL, Picozzi R, et al. Long-term efficacy of captopril in congestive heart failure. Drugs Under Experimental and Clinical Research 10: 723–733, 1984Google Scholar
  141. Fommei E, Ghione S, Ferrari M, Mosca F, Bertelli P, et al. Captopril scintigraphy in arterial hypertension: evaluation of scintigraphic results in relation to blood pressure and renin responses. Journal of Hypertension 4(Supp. 5): S282–S284, 1986Google Scholar
  142. Forslund T, Fyhrquist F, Hostling L. Sustained antihypertensive effect of captopril combined with diuretics and beta adrenergic blocking drugs in patients with resistant hypertension. Acta Medica Scandinavica 213: 299–303, 1983PubMedGoogle Scholar
  143. Fouad FM, Tarazi RC, Bravo EL, Hart NJ, Castle LW, et al. Long term control of congestive heart failure with captopril. American Journal of Cardiology 49: 1489–1496, 1982PubMedGoogle Scholar
  144. Freis ED. Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril). American Journal of Cardiology 61: 117–121, 1988PubMedGoogle Scholar
  145. Fruncillo RJ, Rotmensch HH, Vlasses PH, Koplin JR, Swanson BN, et al. Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives. European Journal of Clinical Pharmacology 28: 5–9, 1985PubMedGoogle Scholar
  146. Fujita T, Ando K, Noda H, Sato Y, Yamashita N, et al. Hemodynamic and endocrine changes associated with captopril in diuretic-resistant hypertensive patients. American Journal of Medicine 73: 341–347, 1982PubMedGoogle Scholar
  147. Fuller RW, Choudry NB. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. British Medical Journal 295: 1025–1026, 1987PubMedGoogle Scholar
  148. Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. American Journal of Cardiology 55: 1110–1113, 1985PubMedGoogle Scholar
  149. Furke PT, Ivashkiv E, Malley MF, Cohen AI. Gas chromatography/selected ion monitoring mass spectrometric determination of captopril in human blood. Analytical Chemistry 52: 1086–1089, 1980Google Scholar
  150. Gagnadoux MF, Niaudet P, Bacri JL, Antignac C, Broyer M. Captopril and transplant renal artery stenosis in children. Transplantation Proceedings 17: 187–188, 1985Google Scholar
  151. Gambaro G, Morbiato F, Cicerello E, Del Turco M, Sartori L, et al. Captopril in the treatment of hypertension in type I and type II diabetic patients. Journal of Hypertension 3(Suppl. 2): S149–S151, 1985PubMedGoogle Scholar
  152. Garanin G. A comparison of once-daily antihypertensive therapy with captopril and enalapril. Current Therapeutic Research 40: 567–575, 1986Google Scholar
  153. Gavras I, Graff LG, Rose BD, McKenna JM, Brunner HR, et al. Fatal pancytopenia associated with the use of captopril. Annals of Internal Medicine 94: 58–59, 1981PubMedGoogle Scholar
  154. Geppetti P, Spillantini MG, Frilli S, Pietrini U, Fanciullacci M, et al. Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid. Journal of Hypertension 5: 151–154, 1987PubMedGoogle Scholar
  155. Giani R, Sacchetti G, Greco L. Captopril and hydrochlorothiazide in elderly patients with mild-moderate hypertension. Clinical Trials Journal 22: 175–178, 1985Google Scholar
  156. Giudicelli JF, Changnon M, Richer C, Giroux B, Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. British Journal of Clinical Pharmacology 18: 749–758, 1984PubMedGoogle Scholar
  157. Gluck Z, Beretta-Piccoli C, Reubi FC. Long-term effects of captopril on renal function in hypertensive patients. European Journal of Clinical Pharmacology 26: 315–323, 1984PubMedGoogle Scholar
  158. Goldsmith SR, Francis GS, Cowley Jr AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. Journal of the American College of Cardiology 1: 1385–1390, 1983PubMedGoogle Scholar
  159. Gomez Reyes D, Rojas Hidalgo E. Efecto de un inhibidor de la enzima conversiva de la angiotensina I (captopril) en diabéticos hipertensos sin nefropatia. Medicina Clinica 90: 531–534, 1988PubMedGoogle Scholar
  160. Greminger P, Foerster E, Vetter H, Baumgart P, Vetter W. Minoxidil and captopril in severe hypertension. Klinische Wochenschrift 64: 327–332, 1986PubMedGoogle Scholar
  161. Groel JT, Tadros SS, Dreslinski GR, Jenkins AC. Long term antihypertensive therapy with captopril. Hypertension 5(Suppl. III): 145–151, 1983Google Scholar
  162. Grosskopf I, Rabinovitz M, Garty M, Rosenfeld JB. Persistent captopril-associated taste alternation. Clinical Pharmacy 3: 235, 1984PubMedGoogle Scholar
  163. Guazzi MD, DeCesare N, Galli C, Salvioni A, Tramontana C, et al. Calcium channel blockade with nifedipine and angiotensin converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation 70: 279–284, 1984PubMedGoogle Scholar
  164. Guivarc’h PH. Captopril versus acebutolol in the treatment of diabetic patients with moderate essential hypertension. Abstract. Postgraduate Medical Journal 64(Suppl. 3): 86, 1988Google Scholar
  165. Havelka J, Boerlin HJ, Studer A, Greminger P, Tenschert W, et al. Long term experience with captopril in severe hypertension. British Journal of Clinical Pharmacology 14(Suppl. 2): 71S–76S, 1982PubMedGoogle Scholar
  166. Hayashi K, Miyamoto M, Sekine Y. Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography. Journal of Chromatography 338: 161–169, 1985PubMedGoogle Scholar
  167. Heald AF, Ita CE. Distribution in rats of an inhibitor of angiotensin-converting enzyme, SQ 14,225, as studied by whole-body autoradiography and liquid scintillation counting. Pharmacologist 19: 129, 1977Google Scholar
  168. Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452, 1980PubMedGoogle Scholar
  169. Hegele RA. Haemolytic anaemia: possible complication of captopril therapy. Canadian Medical Association Journal 129: 525–526, 1983PubMedGoogle Scholar
  170. Herlitz H, Ahlonen J, Aurell M, Blohmé I, Bryngen H, et al. Captopril in hypertension after renal transplantation. Scandinavian Journal of Urology and Nephrology (Suppl. 79): 111–114, 1984Google Scholar
  171. Hermanovich J, Awan NA, Liu H, Mason DT. Comparative analysis of the hemodynamic actions of captopril and sodium nitroprusside in severe chronic congestive heart failure. American Heart Journal 104: 1211–1214, 1982PubMedGoogle Scholar
  172. Hill JF, Bulpitt CJ, Fletcher AE. Angiotensin converting enzyme inhibitors and quality of life: The European Trial. Journal of Hypertension 3(Suppl. 2): S91–S94, 1985PubMedGoogle Scholar
  173. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, et al. Worsening of anaemia induced by long-term use of captopril in hemodialysis patients. American Journal of Nephrology 4: 355–360, 1984PubMedGoogle Scholar
  174. Hirakata H, Onoyama K, Iseki K, Omae T, Sujimi S, et al. Captopril (SQ 14,225) clearance during haemodialysis treatment. Clinical Nephrology 16: 321–323, 1981PubMedGoogle Scholar
  175. Hisano S, Harada T, Fukushige J, Goya N. Low dose administration of captopril in severely hypertensive children. Acta Paediatrica Japonica 26: 205–210, 1984Google Scholar
  176. Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, et al. Factors related to first dose hypotensive effect of captopril: prediction and treatment. British Medical Journal 286: 832–834, 1983PubMedGoogle Scholar
  177. Holland OB, Von Kuhnert L, Campbell WB, Anderson RJ. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension 5: 235–239, 1983PubMedGoogle Scholar
  178. Hollenberg NK. Renal haemodynamics in essential and renovascular hypertension: influence of captopril. American Journal of Medicine 76: 22–28, 1984PubMedGoogle Scholar
  179. Hommel E, Parving H-E, Mathieson E, Edsberg B, Nielsen MD. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. British Medical Journal 293: 467–470, 1986PubMedGoogle Scholar
  180. Hoorntje SJ, Donker AJM, Prins EJL, Weening JJ. Membranous glomerulopathy in a patient on captopril. Acta Medica Scandinavica 208: 325–329, 1980PubMedGoogle Scholar
  181. Hornych A, Safar M, Simon A, Levenson J, Bariety J, et al. Effects of captopril on prostaglandin and natriuresis in patients with essential hypertension. American Journal of Cardiology 49: 1524–1526, 1982PubMedGoogle Scholar
  182. Huang CM, del Greco F, Quintanilla A, Molteni A. Comparison of antihypertensive effects of captopril and propranolol in essential hypertension. Journal of the American Medical Association 245: 478–482, 1981PubMedGoogle Scholar
  183. Hymes LC, Warshaw BL. Long term treatment of hypertension in a preterm infant and in older children. American Journal of Diseases of Childhood 137: 263–266, 1983Google Scholar
  184. Ikram H, Maslowski A, Nicholls MG, Espirer EA, Hull FTL. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. British Heart Journal 48: 541–545, 1982PubMedGoogle Scholar
  185. Imai Y, Abe K, Seino M, Haruyama T, Tajima J, et al. Attenuation of pressor responses to norepinephrine and pitressin and potentiation of pressor response to angiotensin II by captopril in human subjects. Hypertension 4: 444–451, 1982aPubMedGoogle Scholar
  186. Imai Y, Abe K, Seino M, Haruyama T, Tajima J, et al. Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. American Journal of Cardiology 49: 1537–1539, 1982bPubMedGoogle Scholar
  187. Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgraduate Medical Journal 64(Suppl. 3): 59–62, 1988PubMedGoogle Scholar
  188. Iro H, Henschke F, König H-J. Reversible Panmyelopathie nach Captopril-Medikation. Deutsche Medizinische Wochenschrift 111: 139–141, 1986PubMedGoogle Scholar
  189. Israeli A, Or R, Leitersdorf E. Captopril-associated transient aplastic anemia. Acta Haematologica 73: 106–107, 1985PubMedGoogle Scholar
  190. Ivashkiv E. Spectrofluorometric determination of captopril plus captopril disulfide metabolites in plasma. Journal of Pharmaceutical Sciences 73: 1427–1430, 1984PubMedGoogle Scholar
  191. Ivashkiv E, McKinstry DN, Cohen AI. Determination of total captopril in human plasma by gas chromatography-mass spectrometry with selected-ion monitoring after reduction of disulfides. Journal of Pharmaceutical Sciences 73: 1113–1117, 1984PubMedGoogle Scholar
  192. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barradas MA, et al. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. Journal of Human Hypertension 2: 21–25, 1988PubMedGoogle Scholar
  193. Jarrott B, Anderson A, Hooper R, Louis WJ. High-performance liquid Chromatographic analysis of captopril in plasma. Journal of Pharmaceutical Sciences 70: 665–667, 1981PubMedGoogle Scholar
  194. Jarrott B, Drummer O, Hooper R, Anderson AIE, Miach PJ, et al. Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects. American Journal of Cardiology 49: 1547–1549, 1982PubMedGoogle Scholar
  195. Jemal M, Ivashkiv E, Cohen AI. Simultaneous determination of captopril and S-benzoyl captopril in human blood by capillary gas chromatography-mass selective detection. Biomedical Mass Spectrometry 12: 664–667, 1985PubMedGoogle Scholar
  196. Jenkins AC, Dreslinski GR, Tadros SS, Groel JT, Fand R, et al. Captopril in hypertension: seven years later. Journal of Cardiovascular Pharmacology 7: S96–S101, 1985aPubMedGoogle Scholar
  197. Jenkins AC, Knill JR, Dreslinski GR. Captopril in the treatment of the elderly hypertensive patient. Archives of Internal Medicine 145: 2029–2031, 1985bPubMedGoogle Scholar
  198. Jenkins AC, McKinstry DN. Review of clinical studies of hypertensive patients treated with captopril. Medical Journal of Australia 2 (No. 8, Suppl.): 32–37, 1979Google Scholar
  199. Jett GK. Captopril-induced angioedema. Annals of Emergency Medicine 13: 489–490, 1984PubMedGoogle Scholar
  200. Johns DW, Ayers CR, Williams SC. Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients. Hypertension 6: 545–550, 1984PubMedGoogle Scholar
  201. Johns DW, Baker KM, Ayers CR, Vaughan ED, Carey RM, et al. Acute and chronic effect of captopril in hypertensive patients. Hypertension 2: 567–575, 1980PubMedGoogle Scholar
  202. Johnston CI, McGrath BP, Matthews PG. Comparison of the hormonal effects of captopril (SQ 14225) and hydrochlorothiazide in the treatment of essential hypertension. Medical Journal of Australia 2 (Suppl.): 17–22, 1979bGoogle Scholar
  203. Johnston CI, McGrath BP, Millar JA, Matthews PG. Long-term effects of captopril (SQ 14225) on blood pressure and hormone levels in essential hypertension. Lancet 2: 493–495, 1979aPubMedGoogle Scholar
  204. Karlberg BE, Asplund J, Wettre S, Öhman KP, Nilsson OR. Long term experience of captopril in the treatment of primary (essential) hypertension. British Journal of Clinical Pharmacology 14: 133S–137S, 1982PubMedGoogle Scholar
  205. Karlberg BE, Ohman KP, Nilsson OR, Wettre S. Captopril lowers urinary kallikrein in hypertensive patients. Lancet 1: 150–151, 1980PubMedGoogle Scholar
  206. Karlberg BE, Sjöstrand Å, Öhman P. Different effects of two angiotensin converting enzyme inhibitors in primary hypertension: a comparison of captopril and enalapril. Journal of Hypertension 4(Suppl. 5): S432–S434, 1986PubMedGoogle Scholar
  207. Kastanos N, Miró RE, Agustí-Vidal A. Captopril in pulmonary hypertension. British Heart Journal 49: 513–514, 1983PubMedGoogle Scholar
  208. Katz LA. Captopril for geriatric hypertensives. Journal of Hypertension 4(Suppl. 5): S426–S428, 1986Google Scholar
  209. Kawahara Y, Hisaoka M, Yamazaki Y, Inage A, Morioka T. Determination of captopril in blood and urine by high-performance liquid chromatography. Chemical and Pharmaceutical Bulletin 29: 150–157, 1981Google Scholar
  210. Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50mg, hydrochlorothiazide 25mg and their combination in mild to moderate hypertension. British Journal of Clinical Pharmacology 23(Suppl. 1): 89S–92S, 1987PubMedGoogle Scholar
  211. Kikis D, Heck I. Therapie der chronischen Herzinsuffizienz (NYHA III und IV) mit Captopril-Akut- und Langzeitergebrisse. Herz 18: 496–504, 1986Google Scholar
  212. Kiowski W, van Brummelen P, Multhen L, Amann FW, Bühler FR. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clinical Pharmacology and Therapeutics 31: 677–684, 1982PubMedGoogle Scholar
  213. Kirchertz EJ, Gröne HJ, Rieger J, Hölscher M, Scheler F. Successful low dose captopril rechallenge following drug-induced leucopenia. Lancet 1: 1362–1363, 1981Google Scholar
  214. Kisch ES. Captopril and proteinuria in diabetes mellitus. Irish Journal of Medical Sciences 23: 833–834, 1987Google Scholar
  215. Kleber FX, Laube A, Osterkorn K, Konig E. Captopril in mild to moderate heart failure over 18 months: effects on morbidity and mortality. Abstract. Journal of the American College of Cardiology 9: 42A, 1987Google Scholar
  216. Kluger J, Cody RJ, Laragh JH. The contribution of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). American Journal of Cardiology 49: 1667–1674, 1982PubMedGoogle Scholar
  217. Kochar MS, Woods K, Kalbfleisch JH, Puig X. Enalapril vs captopril as step II and methyldopa as step III drugs in hypertension. Current Therapeutic Research 38: 694–701, 1985Google Scholar
  218. Koch-Weser J, Vidt DG, Bravo EL, Fouad FM. Captopril. New England Journal of Medicine 306: 214–219, 1982Google Scholar
  219. Komai T, Ikeda T, Kawai K, Kameyama E, Shindo H. In vitro studies on the metabolic pathway of SQ 14225 (captopril) and mechanism of mixed disulfide formation. Journal of Pharmacobio-Dynamics 4: 677–684, 1981PubMedGoogle Scholar
  220. Kono T, Ikeda F, Oseko F, Imura H, Endo J. Effects of angiotensin-I converting enzyme inhibitor, SQ 14225, in normal men. Endocrinologica Japonica 26: 411–418, 1979Google Scholar
  221. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 67: 807–816, 1983PubMedGoogle Scholar
  222. Kripalani KJ, McKinstry DN, Singhvi SM, Willard DA, Vukovich RA, et al. Disposition of captopril in normal subjects. Clinical Pharmacology and Therapeutics 27: 636–641, 1980PubMedGoogle Scholar
  223. Kristinsson A, Hardarson T, Palsson K, Petursson MK, Snorrason SP, et al. Additive effects of moderate dietary salt reduction and captopril in hypertension. Acta Medica Scandinavica 223: 133–137, 1988PubMedGoogle Scholar
  224. Kubo S, Nishioka A, Nishimura H, Kawamura K, Takatsu T. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. Clinical Pharmacology and Therapeutics 36: 456–463, 1984PubMedGoogle Scholar
  225. Kubo S, Nishioka A, Nishimura H, Kawamura K, Takatsu T. Effects of converting-enzyme inhibition on cardiorenal hemodynamics in patients with chronic congestive heart failure. Journal of Cardiovascular Pharmacology 7: 753–759, 1985PubMedGoogle Scholar
  226. Kubo S, Nishioka A, Nishimura H, Kawamura K, Takatsu T. Effects of captopril on cardiorenal hemodynamics in patients with severe chronic congestive heart failure. Clinical and Experimental Hypertension — Theory and Practice A9: 575–581, 1987Google Scholar
  227. Kugler J, Maskin C, Frishman WH, Sonnenblick EH, LeJemtel TH. Regional and systemic metabolic effects of angiotensinconverting enzyme inhibition during exercise in patients with severe heart failure. Circulation 66: 1256–1261, 1982PubMedGoogle Scholar
  228. Lacourciere Y. Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril. American Journal of Medicine 84(Suppl. IB): 47–52, 1988PubMedGoogle Scholar
  229. Laher MS, O’Regan PO, Donohoe JF, Counihan TB. Captopril for refractory hypertension in patients with impaired renal function. Journal of the Royal Society of Medicine 78: 367–371, 1985PubMedGoogle Scholar
  230. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35, in press, 1988Google Scholar
  231. Leary WP, Reyes AJ, Acosta-Barrios T, Maharaj B. Captopril once daily in patients with essential hypertension and hyperuricaemia. South African Medical Journal 68: 642–644, 1985aPubMedGoogle Scholar
  232. Leary WP, Reyes AJ, van der Byl KV, Acosta-Barrios TN. Effects of captopril, hydrochlorothiazide and their combination on timed urinary excretions of water and solutes. Journal of Cardiovascular Pharmacology 7: S56–S62, 1985bPubMedGoogle Scholar
  233. Lechi A, Covi G, Capuzzo MG, Lechi C, Minuz P, et al. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels. International Journal of Clinical Pharmacology, Therapy and Toxicology 21: 569–574, 1982Google Scholar
  234. Lederle RM. Captopril and hydrochlorothiazide in the fixed combination multicentre trial. Journal of Cardiovascular Pharmacology 7: S63–S69, 1985PubMedGoogle Scholar
  235. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257–267, 1986PubMedGoogle Scholar
  236. Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, et al. Captopril in primary pulmonary hypertension. Circulation 67: 155–161, 1983PubMedGoogle Scholar
  237. Leijten PAA, Willard DA, Manning J, Ivashkiv E, Jemal M, et al. Absence of pharmacokinetic interaction between captopril and digoxin in healthy subjects. In press, 1988Google Scholar
  238. LeJemtel TH, Keung E, Frishman WH. Hemodynamic effects of captopril in patients with severe chronic heart failure. American Journal of Cardiology 49: 1484–1488, 1982PubMedGoogle Scholar
  239. LeJemtel TH, Maskin CS, Mancini D, Siroway L, Feld H, et al. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation 72: 364–369, 1985PubMedGoogle Scholar
  240. Levigne G, Morand P. Traitement de l’insuffisance cardiquechronique congestive sévère par le captopril. Archives des Maladies du Coeur et des Vaisseaux 75: 339–348, 1982Google Scholar
  241. Levine TB, Cohn JN. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure. American Heart Journal 104: 1159–1164, 1982aPubMedGoogle Scholar
  242. Levine TB, Cohn JN. Factors predicting acute and long-term response to captopril therapy in congestive heart failure. British Journal of Clinical Pharmacology 14(Suppl. 2): 169S–174S, 1982bPubMedGoogle Scholar
  243. Levine TB, Franciosa JA, Cohn JN. Acute and long term response to converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62: 35–41, 1980PubMedGoogle Scholar
  244. Levine TB, Olivari MT, Cohn JN. Hemodynamic and regional blood flow response to captopril in congestive heart failure. American Journal of Medicine 76: 38–42, 1984PubMedGoogle Scholar
  245. Lewis EJ. Proteinuria and abnormalities of the renal glomerulus in patients with hypertension. Clinical and Experimental Pharmacology and Physiology (Suppl. 7): 105–115, 1982Google Scholar
  246. Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehman MR. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects. Journal of Cardiovascular Physiology 7(Suppl. 1): S12–S15, 1985Google Scholar
  247. Libretti A, Catalano M. Captopril in the treatment of hypertension associated with claudication. Postgraduate Medical Journal 62(Suppl. 1): 34–37, 1986PubMedGoogle Scholar
  248. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. American Journal of Cardiology 49: 1561–1563, 1982PubMedGoogle Scholar
  249. Lilly L, Dzau VJ, Williams GH, Hollenberg NK. Captopril vs hydralazine in advanced congestive heart failure: comparison of one year survival. Abstract 1629. Circulation 72(Suppl. III): 408, 1985Google Scholar
  250. Lombardo M, Zaini G, Pastori F, Fusco M, Pacini S, et al. Left ventricular mass and function before and after antihypertensive treatment. Journal of Hypertension 1: 215–219, 1983PubMedGoogle Scholar
  251. Luderer JR, Demers LM, Harrison TS, Hayes Jr AH. Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism. Clinical Pharmacology and Therapeutics 31: 305–311,1982PubMedGoogle Scholar
  252. Luderer JR, Schneck DW, Demers LM, McKinstry DN, Vary JE, et al. The humoral effects of captopril and furosemide in hypertensive patients. Clinical Pharmacology and Therapeutics 27: 268, 1980Google Scholar
  253. MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE, et al. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. British Medical Journal 284: 693–696, 1982PubMedGoogle Scholar
  254. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. Journal of Cardiovascular Medicine 7(Suppl. 1): S82–S87, 1985Google Scholar
  255. Madeddu P, Oppes M, Rubattu S, Bandiera F, Dessí-Fulgheri P, et al. Relation between urinary kallikrein excretion and blood pressure response to a single oral dose of captopril. Clinical and Experimental Hypertension — Theory and Practice A9: 615–621, 1987Google Scholar
  256. Maeda T, Tanaka K, Kawameta W, Komai T, Shindo H. Studies on the metabolism of a new antihypertensive agent, SQ 14,225 (captopril). Abstract presented at the 99th Annual Meeting of the Pharmaceutical Society of Japan, Sapporo, August 28–30, 1979Google Scholar
  257. Magnani B. Converting enzyme inhibition and heart failure. American Journal of Medicine 84(Suppl. 3A): 87–91, 1988PubMedGoogle Scholar
  258. Magrini F, Shimizu M, Roberts N, Fouad F, Tarazi RC, et al. Converting-enzyme inhibition and coronary blood flow. Circulation 75(Suppl. 1): 168–174, 1987Google Scholar
  259. Malatino LS, Stancanelli B, Greco G, Botta G, Tamburino G. Once daily fixed combination captopril plus hydrochlorothiazide in the treatment of mild to moderate essential hypertension. Current Therapeutic Research 41: 625–630, 1987Google Scholar
  260. Mancia G, Parati G, Pomidossi G, Colombo A, Cuspidi C, et al. Evaluation of the antihypertensive effect of once-a-day captopril by 24-hour ambulatory blood pressure monitoring. Journal of Hypertension 5(Suppl. 5): S591–S593, 1987Google Scholar
  261. Mancini DM, Davis L, Wexler JP, Chadwick B, Le Jemtel TH. Dependence of enhanced exercise performance on increased skeletal muscle perfusion during long term captopril therapy in heart failure. Journal of the American College of Cardiology 10: 845–850, 1987PubMedGoogle Scholar
  262. Mann J, Andrassy K, Ritz E. Prazosin und captopril in der Kombinationstherapie de schwer einstellbaren Hypertonie. Therapiewoche 33: 3933–3937, 1983Google Scholar
  263. Manthey J, Osterziel J, Röhrig N, Dietz R, Hackenthal E, et al. Ramipril and captopril in patients with heart failure: effects on haemodynamics and vasoconstrictor systems. American Journal of Cardiology 59: 171D–175D, 1987PubMedGoogle Scholar
  264. Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 626–629, 1984Google Scholar
  265. Marin-Grez M, Bonner G, Gross F. Captopril, kallikrein and hypertension. Lancet 1: 1033, 1980PubMedGoogle Scholar
  266. Markusse HM, Meyboom RHB. Gynaecomastia associated with captopril. Correspondence. British Medical Journal 296: 1262–1263, 1988PubMedGoogle Scholar
  267. Martínez-Benazet J, Rodriguez-Roisin R, Torres A, Roca J, Agusti-Vidal A. Captopril produces a short-term pulmonary vasodilatation in patients with pulmonary hypertension secondary to COPD. Abstract. American Review of Respiratory Disease 129: A88, 1984Google Scholar
  268. Massie B, Kramer BL, Topic N, Henderson SG. Hemodynamic and radionuclide effects of acute captopril therapy for heart failure. Circulation 65: 1374–1381, 1982PubMedGoogle Scholar
  269. Massie BM, Kramer BL, Topic N. Lack of relationship between the short term hemodynamic effects of captopril and subsequent clinical responses. Circulation 69: 1135–1141, 1984PubMedGoogle Scholar
  270. Massie BM, Packer M, Harlon JT, Combs DT. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. Journal of the American College of Cardiology 2: 338–344, 1983PubMedGoogle Scholar
  271. Matsuki Y, Ito T, Fukuhara K, Nakamura T, Kimura M, et al. Determination of captopril and its disulphide in biological fluids. Journal of Chromatography 239: 585–594, 1982PubMedGoogle Scholar
  272. Matthews DM, Wathen CG, Bell D, Collier A, Muir AL, et al. The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics. Postgraduate Medical Journal 62(Suppl. 1): 73–75, 1986PubMedGoogle Scholar
  273. Matthews DM, Wathen CG, Bell D, Collier A, Roulston JE, et al. The use of captopril and captopril plus frusemide as antihypertensive agents in non-insulin dependent diabetes. Journal of Human Hypertension 1: 19–23, 1987PubMedGoogle Scholar
  274. McCaa RE, Hall JE, McCaa CS. The effects of angiotensin Iconverting enzyme inhibitors on arterial blood pressure and urinary sodium excretion: role of renal renin-angiotensin and kallikrein-kinin systems. Circulation Research 43(Suppl. 1): 32–39, 1978Google Scholar
  275. McKinstry DN, Kripalani KJ, Migdalof BH, Willard DA. The effect of repeated administration of captopril (CP) on its disposition in hypertensive patients. Clinical Pharmacology and Therapeutics 27: 270–271, 1980Google Scholar
  276. McKinstry DN, Singhvi SM, Kripalani KJ, Dreyfuss J, Willard DA, et al. Disposition and cardiovascular-endocrine effects of an orally active angiotensin-converting enzyme inhibitor, SQ 14,225, in normal subjects. Clinical Pharmacology and Therapeutics 23: 121–122, 1978Google Scholar
  277. McMurray J, Fraser DM. Captopril, enalapril, and blood glucose. Correspondence. Lancet 1: 1035, 1986PubMedGoogle Scholar
  278. Mezzetti A, Guglielmi MD, Ciampi P, Botta G, Porreca E, et al. Effects of chronic captopril therapy on blood pressure and left ventricular response to exercise in mild to moderate hypertension with and without cardiac hypertrophy. Current Therapeutic Research 42: 286–296, 1987Google Scholar
  279. Migdalof BH, Antonaccio MJ, McKinstry DN, Singhvi SM, Lan S-J, et al. Captopril: pharmacology, metabolism, and disposition. Drug Metabolism Reviews 15: 841–869, 1984PubMedGoogle Scholar
  280. Migdalof BH, Singhvi SM, Kripalani KJ. Thin-layer radiochromatographic determination of captopril (SQ 14,225) and its disulfedimermetabolite in blood. Journal of Liquid Chromatography 3: 857–865, 1980Google Scholar
  281. Millar JA, Johnston CI. Sequential changes in circulating levels of angiotensin I and II, renin and bradykinin after captopril. Medical Journal of Australia 2 (Suppl.): 15–17, 1979Google Scholar
  282. Millar JA, Sturani A, Rubin PC, Lawrie C, Reid JL. Attenuation of the antihypertensive effect of captopril by the opioid receptor antagonist naloxone. Clinical and Experimental Pharmacology and Physiology 10: 253–259, 1983PubMedGoogle Scholar
  283. Mimran A, Brunner HR, Turini GA, Waeber B, Brunner D. Effect of captopril on renal vascular tone in patients with essential hypertension. Clinical Science 57: 421S–423S, 1979PubMedGoogle Scholar
  284. Minematsu K, Yamaguchi T, Tsuchiya M, Ito K, Ikeda M, et al. Effect of angiotensin converting enzyme inhibitor (captopril) on cerebral blood flow in hypertensive patients without a history of stroke. Clinical and Experimental Hypertension — Theory and Practice A9: 551–557, 1987Google Scholar
  285. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: Report of the International Collaborative Study Group. Pediatrics 75: 1091–1100, 1985PubMedGoogle Scholar
  286. Mitchell HC, Pettinger WA, Gianotti L, Reed G, Kirk L, et al. Further studies of the hyperadrenergic state of treated hypertensives: effect of captopril. Clinical and Experimental Hypertension — Theory and Practice A5: 1611–1627, 1983Google Scholar
  287. Miyamori I, Yasuhara S, Takeda Y, Koshida H, Ikeda M, et al. Effects of converting enzyme inhibition on split renal function in renovascular hypertension. Hypertension 8: 415–421, 1986PubMedGoogle Scholar
  288. Mookherjee S, Anderson GH, Eich R, Hill N, Smulyan H, et al. Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertension. American Heart Journal 105: 106–112, 1983PubMedGoogle Scholar
  289. Moore TJ, Crantz FR, Hollenberg NK, Koletsky RJ, Leboff MS, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 3: 168–173, 1981PubMedGoogle Scholar
  290. Mooser V, Waeber G, Bidiville J, Waeber B, Nussberger J, et al. Kalemia during combined therapy with an angiotensin converting enzyme inhibitor and a potassium-sparing diuretic. Journal of Clinical Hypertension 3: 510–513, 1987PubMedGoogle Scholar
  291. Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH. Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion. Journal of Clinical Endocrinology and Metabolism 50: 748–754, 1980PubMedGoogle Scholar
  292. Morice AH, Brown MJ, Lowry R, Higenbottam T. Angiotensinconverting enzyme and the cough reflex. Lancet 2: 1116–1118, 1987PubMedGoogle Scholar
  293. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clinical Pharmacology and Therapeutics 32: 307–312, 1982PubMedGoogle Scholar
  294. Muiesan G, Agabiti-Rosei E, Buoninconti R, Cagli V, Carotti A, et al. Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study. Journal of Hypertension 5(Suppl. 5): S599–S602, 1987aPubMedGoogle Scholar
  295. Muiesan G, Alicandri C, Agabiti-Rosei E, Buoninconti R, Cagli V, et al. A multicentre trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker diuretic treatment. Journal of Clinical Hypertension 3: 144–152, 1987bPubMedGoogle Scholar
  296. Muiesan G, Alicandri CL, Agabiti-Rosei E, Fariello R, Beschi M, et al. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. American Journal of Cardiology 49: 1420–1424, 1982PubMedGoogle Scholar
  297. Muiesan G, Alicandri C, Agabiti-Rosei E, Fariello R, Montini E, et al. Efficacy of low dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic. Journal of International Medical Research 12: 221–228, 1984PubMedGoogle Scholar
  298. Mujais SK, Fouad FM, Tarazi RC. Reversal of left ventricular hypertrophy with captopril: heterogeneity of response among hypertensive patients. Clinical Cardiology 6: 595–602, 1983PubMedGoogle Scholar
  299. Mujais SK, Fouad FM, Textor SC, Tarazi RC, Bravo EL, et al. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. British Heart Journal 52: 63–71, 1984PubMedGoogle Scholar
  300. Müller H-M, Overlack A, Heck I, Kolloch R, Stumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. Journal of Hypertension 3(Suppl. 2): S135–S136, 1985PubMedGoogle Scholar
  301. Nakashima Y, Fouad FM, Tarazi RC. Long-term captopril therapy in congestive heart failure: serial hemodynamic and echocardiographic changes. American Heart Journal 104: 827–833, 1982PubMedGoogle Scholar
  302. Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, et al. Effects of captopril on survival in patients with heart failure. American Journal of Medicine 84(Suppl. 3A): 140–144, 1988PubMedGoogle Scholar
  303. Niarchos AP, Whitman HH, Goldstein JE, Laragh JH. Hemodynamic effects of captopril in pulmonary hypertension of colagen vascular disease. American Heart Journal 104: 834–838, 1982PubMedGoogle Scholar
  304. Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Effects of captopril on peripheral hemodynamics in severe congestive heart failure. Clinical and Experimental Hypertension — Theory and Practice A9: 587–591, 1987Google Scholar
  305. O’Connor DT, Strause L, Saltman P, Parmer RJ, Cervenka J. Serum zinc is unaffected by effective captopril treatment of hypertension. Journal of Clinical Hypertension 3: 405–408, 1987PubMedGoogle Scholar
  306. O’Dea RF, Mirkin BL, Alward CT, Sinaiko AR. Treatment of neonatal hypertension with captopril. Journal of Pediatrics, in press, 1988Google Scholar
  307. O’Donnell D. Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed. Medical Journal of Australia 148: 525–527, 1988PubMedGoogle Scholar
  308. Öhman P, Aurell M, Asplund J, Conradsson T, Delin K, et al. A long term follow up of patients with essential hypertension treated with captopril. Acta Medica Scandinavica 216: 53–56, 1984PubMedGoogle Scholar
  309. Öhman KP, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. Journal of Cardiovascular Pharmacology 7(Suppl. 1): S20–S24, 1985PubMedGoogle Scholar
  310. Omae T, Kamano Y, Yoshida K. Side effects and metabolic effects of converting enzyme inhibitors. Clinical and Experimental Hypertension — Theory and Practice A9: 635–642, 1987Google Scholar
  311. Omata K, Abe K, Tsuroda K, Yasujima M, Chiba S, et al. Role of endogenous angiotensin II and prostaglandins in the -antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension. Clinical and Experimental Hypertension — Theory and Practice A9: 569–574, 1987Google Scholar
  312. Omvik P, Lund-Johanssen P. Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise. Journal of Hypertension 2: 73–80, 1984PubMedGoogle Scholar
  313. Onoyama K, Hirakata H, Iseki K, Fujimi S, Omae T, et al. Blood concentrations and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 3: 456–459, 1981PubMedGoogle Scholar
  314. Packer M. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. International Journal of Cardiology 7: 111–120, 1985PubMedGoogle Scholar
  315. Packer M, Lee WH, Bair J, Medina N, Yashak M. Does vasodilator therapy alter prognosis in patients with severe chronic heart failure: comparative effects of hydralazine and captopril and survival in 175 patients treated over a 6-year period. Abstract. Journal of the American College of Cardiology 3: 561, 1984cGoogle Scholar
  316. Packer M, Lee WH, Medina N, Yashak M. Comparative effects of two converting-enzyme inhibitors on renal function in patients with severe chronic heart failure: a prospective randomized clinical trial. Abstract. Journal of the American College of Cardiology 7(Suppl. A): 70A, 1986aGoogle Scholar
  317. Packer M, Lee WH, Medina N, Yashak M. Influence of renal function on the hemodynamic and clinical responses to long term captopril therapy in severe chronic heart failure. Annals of Internal Medicine 104: 147–154, 1986dPubMedGoogle Scholar
  318. Packer M, Lee WH, Medina N, Yashak M, Kessler PD. Functional renal insufficiency during long term therapy with captopril and enalapril in severe chronic heart failure. Annals of Internal Medicine 106: 346–354, 1987PubMedGoogle Scholar
  319. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. New England Journal of Medicine 315: 847–853, 1986ePubMedGoogle Scholar
  320. Packer M, Medina N, Yushak M. Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. American Heart Journal 104: 1215–1223, 1982PubMedGoogle Scholar
  321. Packer M, Medina N, Yushak M. Efficacy of captopril in lowrenin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. American Journal of Cardiology 54: 771–777, 1984aPubMedGoogle Scholar
  322. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the haemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. Journal of the American College of Cardiology 3: 1035–1043, 1984bPubMedGoogle Scholar
  323. Packer M, Medina N, Yushak M. Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology 57: 1323–1327, 1986bPubMedGoogle Scholar
  324. Packer M, Medina N, Yushak M. Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure. American Journal of Medical Science 291: 8–15, 1986cGoogle Scholar
  325. Packer M, Medina N, Yushak M, Lee WH. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study. American Heart Journal 109: 1293–1299, 1985aPubMedGoogle Scholar
  326. Packer M, Medina N, Yushak M, Lee WH. Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. British Heart Journal 54: 298–304, 1985bPubMedGoogle Scholar
  327. Packer M, Miller J, Medina N, Yushak M. Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure. American Journal of Cardiology 51: 183–188, 1983PubMedGoogle Scholar
  328. Passa Ph, Marre M, Leblanc H. Enalapril, captopril and blood glucose. Correspondence. Lancet 1: 1447, 1986PubMedGoogle Scholar
  329. Paulson OB, Jarden JO, Vorstrup S, Holm S, Godtfredsen J. Effect of captopril on the cerebral circulation in chronic heart failure. European Journal of Clinical Investigation 16: 124–132, 1986PubMedGoogle Scholar
  330. Pereira CM, Tarn YK, Collins-Nakai RL, Ng P. Simplified determination of captopril in plasma by high-performance liquid chromatography. Journal of Chromatography 425: 208–213, 1988PubMedGoogle Scholar
  331. Perrett D, Rudge SR, Drury P. Determination of captopril by an improved high-performance liquid chromatography-electrochemical assay. Biochemical Society Transactions 12: 1059–1060, 1984Google Scholar
  332. Pessina AC, Palatini P, Sperti G, Ventura E, Gava R, et al. Synergistic effect of minoxidil and captopril in patients with refractory hypertension. Current Therapeutic Research 35: 269–276, 1984Google Scholar
  333. Pessina AC, Semplicini A, Rossi G, Gatta A, Palatini P, et al. Effects of captopril on renal function in hypertensive patients. American Journal of Cardiology 49: 1572–1573, 1982PubMedGoogle Scholar
  334. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988PubMedGoogle Scholar
  335. Pickering TG, Case DB, Sullivan PA, Laragh JH. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. American Journal of Cardiology 49: 1566–1568, 1982PubMedGoogle Scholar
  336. Pieri R, Nardecchia A, Pirrelli A. Combined nifedipine and captopril treatment in moderately severe primary hypertension. American Journal of Nephrology 6(Suppl. 1): 111–114, 1986PubMedGoogle Scholar
  337. Pierides AM, Rommel AJ, Heald A, Kurtz SB, Frohnert PP. Captopril elimination during hemodialysis and in chronic renal failure. Transactions of the American Society of Artificial Internal Organs 9: 59A, 1980Google Scholar
  338. Piggott PV, Hill JF, Weston-Davies WH. The use of captopril in severe treatment resistant hypertensive patients. Drugs in Experimental and Clinical Research 6: 533–540, 1980Google Scholar
  339. Pipkin FB, Symonds EM, Turner SR. The effect of captopril (SQ 14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. Journal of Physiology 323: 415–422, 1982Google Scholar
  340. Potter JF, Beevers DG. Comparison of nifedepine and captopril as third-line agents in hypertensive patients uncontrolled with a beta blocker and diuretic therapy. Journal of Clinical Pharmacology 27: 410–444, 1987PubMedGoogle Scholar
  341. Powers ER, Bannerman KS, Stone J, Reison DS, Escala EL, et al. The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure. American Heart Journal 104: 1203–1210, 1982PubMedGoogle Scholar
  342. Powers ER, Chiaramida A, DeMaria AN, Giles TD, Hackshaw B, et al. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. Journal of Cardiovascular Pharmacology 9(Suppl. 3): S82–S88, 1987PubMedGoogle Scholar
  343. Pupita F, Ansuini R, Belogi M, Campolucci G, Gaggi S, et al. Life quality in patients under hypotensive treatment. International Journal of Clinical Pharmacology Research 7: 13–17, 1987PubMedGoogle Scholar
  344. Rademaker M, Shaw TRD, Williams BC, Duncan FM, Corrie J, et al. Intravenous captopril treatment in patients with severe cardiac failure. British Heart Journal 55: 187–190, 1986PubMedGoogle Scholar
  345. Rahmat J, Gelfand RL, Gelfand MC, Winchester JF, Schreiner GE, et al. Captopril-associated cholestatic jaundice. Annals of Internal Medicine 102: 56–58, 1985PubMedGoogle Scholar
  346. Rajagopalan B, Ravie A, Cooper R, Ledingham JGG. Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment. American Journal of Medicine 76: 86–90, 1984PubMedGoogle Scholar
  347. Rasmussen S, Leth A, Ibsen H, Nielsen MD, Nielsen F, et al. Converting enzyme inhibition in mild and moderate essential hypertension. Acta Medica Scandinavica 219: 29–36, 1986PubMedGoogle Scholar
  348. Rett K, Wicklmayr M, Tschollar W, Dietze G, Mehnert H. Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in non-insulin dependent diabetes mellitus. Postgraduate Medical Journal 64(Suppl. 3): 69–73, 1988PubMedGoogle Scholar
  349. Reyes AJ, Leary WP, Acosta-Barrios TN. Once daily administration of captopril and hypotensive effect. Journal of Cardiovascular Pharmacology 7: S16–S19, 1985PubMedGoogle Scholar
  350. Reyes AJ, Leary WP, Acosta-Barrios TN. Further experience with once-daily captopril monotherapy in essential hypertension. Current Therapeutic Research 43: 698–706, 1988Google Scholar
  351. Reynolds CH. Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid. Biochemical Pharmacology 33: 1273–1276, 1984PubMedGoogle Scholar
  352. Ribstein J, Mourad G, Mion C, Mimran A. Chronic angiotensin converting enzyme inhibition as an alternative to native kidneys removal in post-transplant hypertension. Journal of Hypertension 4: S255–S257, 1986Google Scholar
  353. Ricci S, Zaniol P, Teglio V, Baraldi P, Mattioli G. Sustained haemodynamic and clinical effects of captopril in long term treatment of severe chronic congestive heart failure. British Journal of Clinical Pharmacology 14: 209S–215S, 1982PubMedGoogle Scholar
  354. Rich S, Martinez J, Lam W, Rosen KM. Captopril as treatment for patients with pulmonary hypertension. British Heart Journal 48: 272–277, 1982PubMedGoogle Scholar
  355. Richard C, Ricome J-L, Rimailho A, Conrad M, Auzépy P. Effects of captopril on pulmonary haemodynamics. European Journal of Clinical Pharmacology 27: 35–39, 1984PubMedGoogle Scholar
  356. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 2: 709–711, 1987PubMedGoogle Scholar
  357. Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. British Journal of Clinical Pharmacology 17: 243–250, 1984PubMedGoogle Scholar
  358. Riegger AJG, Lieban G, Kochsiek K. Inappropriately high secretion of antidiuretic hormone in patients with severe heart failure before and after captopril treatment. Abstract no. 172. Acta Endocrinologica 102(Suppl. 253): 155–156, 1983Google Scholar
  359. Riobo P, Garcia-Robles R, Estopiñan V, Hurtado A, Sancho-Rof J. Effect of long-term inhibition of converting enzyme on carbohydrate metabolism in non-insulin dependent diabetic patients with essential hypertension. Abstract. Postgraduate Medical Journal 64(Suppl. 3): 63–64, 1988Google Scholar
  360. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo controlled comparison of captopril, atenolol, labetolol and pindolol in hypertension complicated by intermittent claudication. Lancet 2: 650–653, 1987PubMedGoogle Scholar
  361. Romankiewicz JA, Brogden RN, Heel RC, Speight TM, Avery GS. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 25: 6–40, 1983PubMedGoogle Scholar
  362. Romero R, Sanmarti A, Salinas I, Teixido J, Foz M, et al. Utilidad de los inhibidores de la enzima conversiva de la angiotensina en el tratamiento de la nefrapatía diabética. Medicina Clinica 90: 494–496, 1988PubMedGoogle Scholar
  363. Rommel AJ, Pierides AM, Heald A. Captopril elimination in chronic renal failure. Clinical Pharmacology and Therapeutics 27: 282, 1980Google Scholar
  364. Rotmensch HH, Vlasses PH, Ferguson RK. Resolution of captopril-induced rash after substitution of enalapril. Pharmacotherapy 3: 131–133, 1983PubMedGoogle Scholar
  365. Rouleau J-L, Chatterjee K, Berge W, Parmley WW, Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation 65: 671–678, 1982PubMedGoogle Scholar
  366. Rumboldt Z, Marinkovic M, Drinovec J. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension. International Journal of Clinical Pharmacology Research 8: 181–188, 1988PubMedGoogle Scholar
  367. Ryan EA, Muldowney FP. Use of angiotensin I to II converting enzyme inhibitor SP 14225 (Captopril) in moderate essential hypertension. Irish Medical Journal 76: 176–177, 1983Google Scholar
  368. Safar ME. Fatal bone-marrow suppression associated with captopril. British Medical Journal 283: 791–792, 1981PubMedGoogle Scholar
  369. Šagát T, Sasinka M, Furková K, Milovsky V, Riedel R, et al. Treatment of renal hypertension in children by captopril. Clinical and Experimental Hypertension — Theory and Practice 8: 853–857, 1986Google Scholar
  370. Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, et al. Captopril and nifedipine interactions in the treatment of essential hypertensions: a crossover study. Journal of Hypertension 5(Suppl. 4): S139–S142, 1987PubMedGoogle Scholar
  371. Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadel L, et al. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. Journal of Cardiovascular Pharmacology 7: S25–S29, 1985PubMedGoogle Scholar
  372. Salvetti A, Pedrinelli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to captopril patients with essential hypertension. Clinical Science 63: 261S–263S, 1982Google Scholar
  373. Salvetti A, Sassano P, Pedrinelli R, Arzilli F. The influence of indomethacin on pharmacological actions of captopril in renovascular patients. Drugs Under Experimental and Clinical Research 6: 541–551, 1980Google Scholar
  374. Samanta A, Burden AC. Peripheral neuropathy due to captopril. British Medical Journal 291: 1172, 1985Google Scholar
  375. Santucci A, Aguglia F, DeMattia G, Cammarella I, Giordano M, et al. Effects of captopril on blood pressure and renin-angiotensin-aldosterone system in hypertensive subjects after inhibition of renal vasodilative system. International Journal of Clinical and Pharmacology Research 4: 41–45, 1984Google Scholar
  376. Santucci A, Aguglia F, DeMattia G, Ficara C, Balsano F. Long term captopril treatment in moderate to severe hypertension. British Journal of Clinical Pharmacology 14: 77S–79S, 1982PubMedGoogle Scholar
  377. Santucci A, Luparini RL, Ferri C, Ficara C, Giarrizzo G, et al. Relationship between vasopressin and the renin-angiotensin-aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin. Journal of Hypertension 3(Suppl. 2): S133–S134, 1985PubMedGoogle Scholar
  378. Schalekamp MADH. Clinical experience with captopril in hypertension. In Progress in Pharmacology, Vol. 5, pp. 69–85, Verlag, Stuttgart, 1984Google Scholar
  379. Schlichtkrull J, Munck O, Jersild M. The ‘M’ value, an index of blood sugar control in diabetes. Acta Medica Scandinavica 177: 95–102, 1985Google Scholar
  380. Schoenberger JA, Wilson DJ. Once daily treatment of essential hypertension with captopril. Journal of Clinical Hypertension 4: 379–387, 1986Google Scholar
  381. Schrader J, Schoel G, Scheler F. Results of a 5-year study of captopril in patients with severe therapy-resistant hypertension (translation). Klinische Wochenschrift 64: 695–700, 1986PubMedGoogle Scholar
  382. Schuna A, Schmidt GR, Pitterle ME. Serum potassium concentrations after initiation of captopril therapy. Clinical Pharmacy 6: 194–195, 1987Google Scholar
  383. Seedat YK, Rawat R. Captopril combined with minoxidil, beta blocker and furosemide in the treatment of refractory hypertension. European Journal of Clinical Pharmacology 25: 9–11, 1983PubMedGoogle Scholar
  384. Sharpe DN, Coxon R. Hemodynamic effects of captopril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. American Heart Journal 104: 1164–1171, 1982aPubMedGoogle Scholar
  385. Sharpe DN, Coxon R. Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. Australian and New Zealand Journal of Medicine 12: 483–488, 1982bPubMedGoogle Scholar
  386. Sharpe N, Murphy J, Smith H, Hannon S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1: 255–259, 1988PubMedGoogle Scholar
  387. Shaw TRD, Duncan FM, Williams BC, Crichton E, Thomson SA, et al. Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure. British Heart Journal 54: 160–165, 1985PubMedGoogle Scholar
  388. Sheiban I, Arcaro G, Covi G, Accardi R, Zenorini C, et al. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril. Journal of Cardiovascular Pharmacology 10(Suppl. 10): 187–191, 1987Google Scholar
  389. Shepherd AN, Campbell BC, Reid JL. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers. Journal of Cardiovascular Pharmacology 4: 381–387, 1982PubMedGoogle Scholar
  390. Shepherd AN, Hayes PC, Jacyna M, Morrison L, Bouchier IAD. The influence of captopril, the nitrates and propranolol on apparent liver blood flow. British Journal of Clinical Pharmacology 19: 393–397, 1985PubMedGoogle Scholar
  391. Shimada K, Tanaka M, Nambara T, Imai Y, Abe K, et al. Determination of captopril in human blood by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 227: 445–451, 1982PubMedGoogle Scholar
  392. Shindo K, Matsuya F, Ura T, Jodai A, Shinomae H, et al. Captopril-associated granulocytopenia in hypertension after renal transplantation. Clinical Nephrology 22: 314–316, 1984PubMedGoogle Scholar
  393. Shionoiri H, Kaneko Y. Angiotensin converting enzyme inhibitors and the therapy of hypertension. Cited in Omae et al. Clinical and Experimental Hypertension — Theory and Practice A9: 635–642, 1987Google Scholar
  394. Shionoiri H, Miyakawa T, Takasaki I, Ishikawa I, Hiroto S, et al. Glucose tolerance during chronic captopril therapy in patients with essential hypertension. Journal of Cardiovascular Pharmacology 9: 160–164, 1987PubMedGoogle Scholar
  395. Sigström L, Aurell M, Jodal U. Angiotensin converting enzyme inhibitor treatment of hypertension in infancy and childhood. Scandinavian Journal of Urology and Nephrology Suppl. 79: 107–109, 1984Google Scholar
  396. Silberbauer K, Punzengruber C, Sinzinger H. Endogenous prostaglandin E2 metabolite levels, renin-angiotensin system and catecholamines versus acute haemodynamic response to captopril in chronic congestive heart failure. Cardiology 70: 297–307, 1983PubMedGoogle Scholar
  397. Silberbauer K, Stanek B, Tempi H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. British Journal of Clinical Pharmacology 14: 87S–93S, 1982PubMedGoogle Scholar
  398. Simon AC, Levenson JA, Bouthier J, Maarek B, Safar ME. Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension. Journal of Cardiovascular Pharmacology 7(Suppl.): S45–S51, 1985PubMedGoogle Scholar
  399. Simon AC, Safar ME, Levenson JA, Bouthier JE, Benetos A. Action of vasodilating drugs on small and large arteries of hypertensive patients. Journal of Cardiovascular Pharmacology 5: 626–631, 1983PubMedGoogle Scholar
  400. Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clinical and Experimental Hypertension — Theory and Practice 8: 829–839, 1986Google Scholar
  401. Singer DRJ, Markandu ND, Shore AC, MacGregor GA. Captopril and nifedipine in combination for moderate to severe essential hypertension. Hypertension 9: 629–633, 1987PubMedGoogle Scholar
  402. Singhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH. Renal handling of captopril: effect of probenecid. Clinical Pharmacology and Therapeutics 32: 182–189, 1982aGoogle Scholar
  403. Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. Journal of Clinical Pharmacology 22: 135–140, 1982bPubMedGoogle Scholar
  404. Smit AJ, Hoorntje SJ, Donker AJM. Zinc deficiency during captopril treatment. Nephron 34: 196–197, 1983PubMedGoogle Scholar
  405. Smit AJ, Van Der Laan S, De Morichy J, Kallenberg CGM, Donker AJM. Cutaneous reactions to captopril: predictive value of skin tests. Clinical Allergy 14: 413–419, 1984PubMedGoogle Scholar
  406. Someya N, Kodama K, Tanaka K. Effect of captopril on plasma prostacyclin concentration in essential hypertensive patients. Prostaglandins Leukotrienes and Medicine 20: 187–195, 1985Google Scholar
  407. Staessen J, Boogaerts M, Fagard R, Amery A. Mechanism of captopril-induced agranulocytosis. Acta Clinica Belgica 36: 87–90, 1981PubMedGoogle Scholar
  408. Staessen J, Fagard R, Lijnen P, Verschueren LJ, Amery A. Doubleblind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients. American Heart Journal 106: 321–328, 1983PubMedGoogle Scholar
  409. Stornello M, Di Rao G, Iachello M, Pisani R, Scapellato L, et al. Haemodynamic and hormonal interactions between captopril and nifedipine. Hypertension 5(Suppl. III): III156–III156, 1983Google Scholar
  410. Strair RK, Mitch WE, Faller DV, Skorecki KL. Reversible captopril-associated bone marrow aplasia. Canadian Medical Association Journal 132: 320–322, 1985PubMedGoogle Scholar
  411. Stumpe KO, Overlack A, Kolloch R, Schreyer S. Long term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild to moderate essential hypertension. British Journal of Clinical Pharmacology 14: 121S–126S, 1982PubMedGoogle Scholar
  412. Sullivan PA, Kelleher M, Twomey M, Dineen M. Effects of converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension. Journal of Hypertension 3: 359–363, 1985PubMedGoogle Scholar
  413. Swartz SL, Williams GH. Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology 49: 1405–1409, 1982PubMedGoogle Scholar
  414. Swartz SL, Williams GH, Hollenberg NK, Crantz FR, Moore TJ, et al. Endocrine profile in the long-term phase of converting enzyme inhibition. Clinical Pharmacology and Therapeutics 28: 499–508, 1980PubMedGoogle Scholar
  415. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, et al. Effect of captopril on heavy proteinuria in azotemic patients. New England Journal of Medicine 313: 1617–1620, 1985PubMedGoogle Scholar
  416. Takada K, Hayashi M, Takahashi K, Yasui S. Acute effects of oral captopril on hemodynamics in patients with cor pulmonale. Japanese Circulation Journal 50: 1055–1061, 1986PubMedGoogle Scholar
  417. Tarazi RC, Bravo EL, Fouad FM, Omvik P, Cody RJ. Haemodynamic and volume changes associated with captopril. Hypertension 2: 576–585, 1980PubMedGoogle Scholar
  418. Textor SC, Tarazi RC, Novick AC, Bravo EL, Fouad FM. Regulation of renal haemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. American Journal of Medicine 76: 29–37, 1984PubMedGoogle Scholar
  419. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. Journal of the American Medical Association 259: 539–544, 1988Google Scholar
  420. Thibonnier M, Soto ME, Ménard J, Aldiger JC, Corvol P, et al. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. European Journal of Clinical Investigation 11: 449–453, 1981PubMedGoogle Scholar
  421. Thind GS, Johnson A, Bhatnagar D, Henkel TW. A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension. American Heart Journal 109: 852–858, 1985PubMedGoogle Scholar
  422. Thind GS, Mahapatra RK, Johnson A, Coleman RD. Low dose captopril titration in patients with moderate to severe hypertension treated with diuretics. Circulation 67: 1340–1346, 1983PubMedGoogle Scholar
  423. Thomsen OØ, Danielsen H, Sørensen SS, Pedersen EB. Effect of captopril on renal haemodynamics and the renin-angiotensinaldosterone and osmoregulatory systems in essential hypertension. European Journal of Clinical Pharmacology 30; 1–6, 1986PubMedGoogle Scholar
  424. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Archives of Internal Medicine 144: 733–735, 1984PubMedGoogle Scholar
  425. Timmermans PBMWM, Wilffert B, Kulkman HO, Thoolen MJMC. Selective inhibition of α2-adrenoceptor mediated vasoconstriction in vivo by captopril and MK-421. British Journal of Pharmacology 75 (Suppl.): 135P, 1982Google Scholar
  426. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986PubMedGoogle Scholar
  427. Topic N, Kramer B, Massie B. Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. American Heart Journal 104: 1172–1179, 1982PubMedGoogle Scholar
  428. Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. Journal of Pediatrics 112: 295–298, 1988PubMedGoogle Scholar
  429. Traub YM, Levey BA. Combined treatment with minoxidil and captopril in refractory hypertension. Archives of Internal Medicine 143: 1142–1144, 1983PubMedGoogle Scholar
  430. Tu J, Lin E, Nickoloff EL. A radioimmunoassay for total captopril in human serum or plasma samples. Therapeutic Drug Monitoring 6: 59–65, 1984PubMedGoogle Scholar
  431. Tuck ML, Katz LA, Kirkendall WM, Koeppe PR, Ruoff GE, et al. Low dose captopril in mild to moderate geriatric hypertension. Journal of the American Geriatrics Society 34: 693–696, 1986PubMedGoogle Scholar
  432. Valvo E, Bedogna V, Casagrande P, Panebianco R, Bommartini F, et al. Effects of captopril on systemic and renal haemodynamics in patients with diabetic nephropathy and renal insufficiency. Abstract. Postgraduate Medical Journal 64(Suppl. 3): 89, 1988Google Scholar
  433. Vandenburg MJ, Holly JMP, Goodwin FJ, Sharman VL, Marsh FP. The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension. European Journal of Clinical Pharmacology 25: 721–728, 1983PubMedGoogle Scholar
  434. Van Leeuwen BH, Millar JA, Hammatt MT, Johnston CI. Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen. Clinica Chimica Acta 127: 343–351, 1983Google Scholar
  435. Venkatachalam K, Kosanovich JM. Captopril in hypertension after renal transplantation. Clinical Nephrology 19: 265–268, 1983PubMedGoogle Scholar
  436. Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardon MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. American Journal of Cardiology 55: 1023–1026, 1985PubMedGoogle Scholar
  437. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Captopril: evaluation of low doses, twicedaily doses and the addition of diuretic for the treatment of mild to moderate hypertension. Clinical Science 63: 443–445, 1982bGoogle Scholar
  438. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. British Journal of Clinical Pharmacology 14: 97S–101S, 1982aGoogle Scholar
  439. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Low dose captopril for the treatment of mild to moderate hypertension. Hypertension 5(Suppl. III): 139–144, 1983Google Scholar
  440. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension. Clinical Pharmacology and Therapeutics 36: 307–314, 1984Google Scholar
  441. Vlasses PH, Conner DP, Rotmensch HH, Fruncillo RJ, Danzeisen JR, et al. Double-blind comparison of captopril and enalapril in mild to moderate hypertension. Journal of the American College of Cardiology 7: 651–660, 1986PubMedGoogle Scholar
  442. Vlasses PH, Ferguson RK, Smith JB, Rotmesch HH, Swanson BN. Urinary excretion of prostacyclin and thromboxane A2-metabolites after angiotensin converting enzyme inhibition in hypertensive patients. Prostaglandins Leukotrienes and Medicine 11: 143–150, 1983Google Scholar
  443. Vlasses PH, Koffer H, Ferguson RK, Green PJ, McElwain GE. Captopril withdrawal after chronic therapy. Clinical and Experimental Hypertension 3: 929–937, 1981PubMedGoogle Scholar
  444. Vlasses PH, Rotmensch HH, Swanson BN, Mojaverian P, Ferguson RK. Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment. Archives of Internal Medicine 142: 1098–1101, 1982PubMedGoogle Scholar
  445. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, et al. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236–242, 1980PubMedGoogle Scholar
  446. Waeber B, Schaller M-D, Wauters J-P, Brunner HR. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalisation with captopril. Klinische Wochenschrift 62: 728–730, 1984PubMedGoogle Scholar
  447. Walsh WF, Lee CL. Acute and chronic effects of captopril therapy in patients with refractory heart failure. British Journal of Clinical Pharmacology 14(Suppl. 2): 153S–159S, 1982PubMedGoogle Scholar
  448. Walsh KP, Walsh MJ, Branagan JP. Reversible severe thrombocytopaenia associated with captopril. Irish Medical Journal 79: 43–44, 1986PubMedGoogle Scholar
  449. Walter NMA, Whitworth IA, Kincaid-Smith P. Captopril in mild and severe hypertension. Clinical and Experimental Pharmacology and Physiology 7: 477–480, 1980PubMedGoogle Scholar
  450. Warren SE, O’Connor DT, Cohen IM. Autonomic and baroreflex function after captopril in hypertension. American Heart Journal 105: 1002–1008, 1983PubMedGoogle Scholar
  451. Watson MA, Radford NJ, McGrath BP, Swinton GW, Agar JWM. Captopril-induced agranulocytosis in systemic sclerosis. Australian and New Zealand Journal of Medicine 11: 79–81, 1981PubMedGoogle Scholar
  452. Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. American Journal of Medicine 84(Suppl. 4A): 16–23, 1988PubMedGoogle Scholar
  453. Weinberger MH. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. British Journal of Clinical Pharmacology 14: 127S–131S, 1982aPubMedGoogle Scholar
  454. Weinberger MH. Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients. American Journal of Cardiology 49: 1542–1543, 1982bPubMedGoogle Scholar
  455. Wenting GJ, De Bruyn JHB, Man In’t Veld AJ, Woittiez AJJ, Derkx FHM, et al. Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin. American Journal of Cardiology 49: 1453–1459, 1982PubMedGoogle Scholar
  456. Wenting GJ, Man in’t Veld AJ, Woittiez AJ, Boomsma F, Laird-Meeter K, et al. Effects of captopril in acute and chronic heart failure: correlations with plasma levels of noradrenaline, renin, and aldosterone. British Heart Journal 49: 65–76, 1983PubMedGoogle Scholar
  457. Wenting GJ, Tan-Tjiong HL, Derkx FHM, de Bruyn JHB, Man in’t Veld AJ, et al. Split renal function after captopril in unilateral renal artery stenosis. British Medical Journal 288: 886–890, 1984PubMedGoogle Scholar
  458. Whitman HH, Case DB, Laragh JH, Christian CL, Botstein G, et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis and Rheumatism 25: 241–248, 1982PubMedGoogle Scholar
  459. Whitworth JA, Walter NMA, Kincaid-Smith P. ‘First dose’ effect of captopril. Australian and New Zealand Journal of Medicine 12: 325–326, 1982PubMedGoogle Scholar
  460. Williams GM, Sugerman AA. The effect of a meal, at various times relative to drug administration, on the bioavailability of captopril. Abstract. Journal of Clinical Pharmacology 22: 18A, 1982Google Scholar
  461. Wilson SK, Lynch DR, Snyder SH. Angiotensin-converting enzyme labeled with [3H] captopril. Journal of Clinical Investigation 80: 841–850, 1987PubMedGoogle Scholar
  462. Wincour PH, Waldek S, Johns CW, Dhar H, Anderson DC. Captopril may adversely affect renal function in hypertensive diabetics without established nephropathy. Journal of Endocrinology 108 (Suppl.): Abstract 216, 1986Google Scholar
  463. Witte PU, Walter U. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension. American Journal of Cardiology 59: 115D–120D, 1987PubMedGoogle Scholar
  464. Witzgall H, Hirsch F, Scherer B, Weber PC. Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin. Clinical Science 62: 611–615, 1982aPubMedGoogle Scholar
  465. Witzgall H, Scherer B, Weber PC. Involvement of prostaglandins in the actions of captopril. Clinical Science 63: 265S–267S, 1982bGoogle Scholar
  466. Wong KK, Lan S-J, Migdalof BH. In vitro biotransformations of [14C]-captopril in the blood of rats, dogs and humans. Biochemical Pharmacology 30: 2643–2650, 1981PubMedGoogle Scholar
  467. Woo J, Woo KS, Kin T, Vallance-Owen J. A single-blind, randomised cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly. Archives of Internal Medicine 147: 1386–1389, 1987PubMedGoogle Scholar
  468. Zawada ET, Clements PJ, Furst DA, Bloomer HA, Paulus HE, et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 27: 74–78, 1981PubMedGoogle Scholar
  469. Zimmerman BG. Actions of angiotensin on adrenergic nerve endings. Federation Proceedings 37: 199–202, 1978PubMedGoogle Scholar
  470. Zumkley H, Bertram HP, Vetter H, Zidek W, Losse H. Zinc metabolism during captopril treatment. Hormone and Metabolic Research 17: 256–258, 1985PubMedGoogle Scholar
  471. Zweifler AJ, Julius S, Nicholls MG. Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension. Archives of Internal Medicine 141: 907–910, 1981PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • Rex N. Brogden
    • 1
  • Peter A. Todd
    • 1
  • Eugene M. Sorkin
    • 1
  1. 1.ADIS Press LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations